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ABSTRACT 
 
The oral hypoglycemic agent Glyburide has been shown to be actively transported 
from various biological tissues though a pronounced interaction with the ATP binding 
cassette (ABC) active transport proteins. Specifically, Glyburide is actively 
transported by the ABC proteins, P-glycoprotein (Pgp), Breast Cancer Resistance 
Protein (BCRP), and the Multidrug Resistance Proteins (MRP). This active transport 
occurs at various locations throughout the body but has been identified as being 
responsible for Glyburide’s unique placental transport behavior. Glyburide has been 
shown to not cross the placental barrier to any appreciable effect and will leave the 
placental barrier against the concentration gradient. Understanding this active 
transport creates the possibility of medicines designed specifically for pregnant 
women. The objective of this thesis is to investigate the activity of Glyburide and a 
series of sulfonylurea analogs against these two ABC transporter proteins. 
The transport of Glyburide and a series of sulfonylurea analogs in the presence of P-
glycoprotein (Pgp) and breast cancer resistance protein (BCRP) was investigated in 
cell-based transport assays using two stably transfected Madin-Darby Canine Kidney 
cell lines, one overexpressing Pgp and the other overexpressing BCRP genes. The 
results of the transport studies confirm that both Pgp and BCRP play a role in the 
transport of the sulfonylureas. Further, in addition to Glyburide, the molecules 
Glimepiride, Glisoxepide, and Gliquidone were confirmed as Pgp and BCRP 
substrates, all of which has not previously been reported. 
Subsequently, the sulfonylurea transport activity with both Pgp and BCRP were used 
as the basis to build quantitative structure activity relationship (QSAR) and 
iii 
 
pharmacophore models. These models suggest that there are core molecular features 
necessary for the Pgp and BCRP activity, specifically that the arylsulfonylurea and 
benzamido ligands are required for both activities. We also found that increased 
hydrophobic character and increased bulky groups are key to both activities. The main 
differences in the activities were surrounding the sulfonylurea and amide moieties, 
with positive charge increasing the BCRP activity, and negative charge increasing the 
Pgp activity. Overall, the results of this research serve to provide improved knowledge 
for the design of pregnancy centered medications. 
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INTRODUCTION 
 
Glyburide (generic, glibenclamide) is a small molecule sulfonylurea used for the 
treatment of hyperglycemia. Glyburide is the most prescribed small molecule for the 
first line of defense or the treatment of Type II Diabetes due to its very attractive 
pharmacological profile.
1
  The sulfonylurea compounds were first discovered by Janbon 
et al.; when researching sulfonamides in patients with typhoid fever, the team noted 
hypoglycemic results, leading to introduction of sulfonylureas to treat hyperglycemia 
into the US commercial market in 1955. 
2
 The sulfonylureas have evolved over two 
generations, though each generation shares the same core sulfonylurea backbone as 
presented in Figure 1.  
 
                                                   
              Figure 1. Sulfonylurea backbone. 
 
Sulfonylureas development has been sixty years in the making, with the first-generation 
molecules developed in 1950-1980’s, and the second-generation molecules developed 
during the 1980-1990’s. The two generations of sulfonylureas differ in the physical-
chemical attributes, and subsequent pharmacokinetic/pharmacodynamic (PK/PD) 
parameters, with the latter generation having an increased safety and efficacy. 
3
 The 
improvements to the physical-chemical and PK/PD parameters are due to the structural 
changes at the para position on the central aryl ring (R1) and functional group R2 
attached to the remote urea position, as detailed in Figure 1. The first-generation 
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sulfonylureas have smaller molecular weights, with more polar and hydrophilic 
substituents. The second-generation sulfonylureas have larger molecular weights, 
containing more non-polar lipophilic substituents. This increased lipophilic character 
allows for easier membrane permeability, and therefore an increased potency.  This is an 
important point to discuss as the target protein, the sulfonylurea receptor (SUR1), is 
membrane bound protein, and having molecules with an increased hydrophobicity 
allows for the molecules to penetrate the membrane more readily, reaching the receptor 
more efficiently. 
4
 The commercial sulfonylurea structures are presented in Figures 2 
and 3.  
 
 
 
 
 
 
 
 
Figure 2. Representative structures of the first-generation sulfonylurea hypoglycemic 
agents. 
 
 
 
 
Glyclopyramide Metahexamide Tolbutamide 
Tolazamide 
Glibornuride Acetohexamide 
Carbutamide 
Chlorpropamide Gliclazide 
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Figure 3. Representative structures of the second-generation sulfonylurea hypoglycemic 
agents. 
 
As expected, the similarity of the core structure of the first and second-generation 
sulfonylureas allow for a similar response to reducing hyperglycemia. 
5
 This can be 
explained in the structure activity relationship research performed for the development 
of the sulfonylureas, as demonstrated by an increase in binding affinity for the 
sulfonylurea receptor 1 (SUR1). The SUR1 receptor is an active transporter that has 
been shown to have multiple binding sites, A and B, with the more potent second-
generation molecules believed to bind to both the A and B sites. For reference, the 
molecules tolbutamide (1
st
 gen) and glyburide (2
nd
 gen) and the representative binding 
sites of SUR1 are presented in Figure 4. 
6
 This increased structure activity relationship 
(SAR) work also presents as a longer half-life, higher lipophilicity, and increased plasma 
protein binding adding to the increase in efficacy and safety. 
7
 
 
Glisoxepide 
Glyburide 
Glipizide 
Glimepiride 
Gliquidone 
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Figure 4. Biding Site of SUR1 protein and 1
st
 and 2
nd
 generation SUs structural map.
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SULFONYLUREAS FOR TYPE II DIABETES  
The sulfonylurea chemical class has been widely used in the treatment of hyperglycemia 
for more than sixty years and is now a popular choice for a first line of treatment in 
diabetes care. Specifically, the sulfonylureas have become an integral treatment option 
for those patients who have not maintained or achieved adequate glycemic control 
through diet and exercise alone. 
9, 10, 11
 The sulfonylureas work by binding to the SUR1 
receptor, which triggers the cascade of two signal pathways that release insulin in the 
pancreatic β-cell. The first pathway is the ATP-sensitive potassium channel (KATP) 
pathway and is the link between glucose metabolism and the stimulation of insulin 
production. The second pathway is a glucose signaling pathway and augments the 
insulin release due to the increase in the Ca
2+
 concentration. 
12
 In this respect, the 
sulfonylureas are insulin secratogues, meaning that the mode of action is similar to that 
of insulin, stimulating the ATP sensitive Potassium (KATP) channels within the 
pancreatic β- cells. 13 In summary, this action stimulates the insulin release via the 
occupation of the β-cell membrane SUR1. 14, 15, 16   In response to an increase in blood 
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glucose concentrations, the enhanced rate of glucose metabolism causes the changes in 
concentrations of the adenosine diphosphate (ADP) and adenosine triphosphate (ATP), 
driving the closure of the pore. The depolarization of the cell membrane is due to a 
decrease in the K+ permeability into the cell and an opening of the Ca
2+
 channels. This 
enhancement of the Ca+2 influx across the cell membrane is the final step of the cascade 
and triggers the release of insulin. 
17
 The dual pathway mechanism of insulin release in 
the pancreatic beta cells is depicted in Figure 5. 
 
        
Figure 5. The mechanism of glucose dependent insulin release in pancreatic β- cells. 18 
 
SIMILARITIES BETWEEN T2D AND GESTATIONAL DIABETES MELLITUS 
STATES 
As part of normal function, the body needs to regulate insulin production as a direct 
response to the increase or decrease in blood sugar levels after food consumption. There 
are two states of blood sugar levels, hyperglycemia and hypoglycemia, which represent 
too much and too little blood sure, respectively. Hyperglycemia can be a chronic 
7 
 
condition in which the body’s inability to produce any or enough insulin causes elevated 
levels of glucose in the blood, and are known as Type I and Type II Diabetes, 
respectively. 
19
 Both types of Diabetes are characterized by an insulin resistance and a 
resultant insulin deficiency. In general terms, Type I diabetes is an autoimmune disorder 
leading to the destruction of pancreatic beta cells and hence the body’s inability to 
produce insulin; and Type II Diabetes is primarily a problem of progressively impaired 
glucose regulation due to the dysfunction of the pancreatic beta cells and general insulin 
resistance.
20, 21
 . Also, Type II diabetes is influenced by many genetic and environmental 
factors, such as obesity and overweight contributing to the insulin resistance, 
compounding the issue. 
22
 Researchers have found that the occurrence rate of Type 1 vs 
Type 2 Diabetes is approximately 10% and 90%, respectively, regardless of country or 
population. 
23
 
Type I diabetes has only one treatment option, daily injections of insulin to directly 
manage blood sugar levels. Type II diabetes, however, has multiple treatment options 
available, including diet, exercise, pharmacological treatment, or a mix of all three.  The 
bulk of the Type II case are treatable with diet and exercise changes alone, with only 
approximately 30% of Type II patients requiring pharmacological treatment. 
24
 
This inability to control blood glucose levels occurs in pregnant women and is referred 
to as pregnancy induced gestational diabetes mellitus (GDM). The definition of GDM is 
carbohydrate intolerance resulting in hyperglycemia, with the onset or recognition 
occurring during pregnancy. 
25 
GDM is a well characterized disease affecting a large 
portion of the population and has been widely linked to the weight gain associated with 
pregnancy. 
26
 Although the exact cause of GDM is not known, there are some theories 
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that may explain the condition and why it occurs. During pregnancy, the placenta 
supplies the fetus with nutrient and water, and produces hormones to maintain the 
pregnancy throughout gestation. Some of these hormones produces a contra-insulin 
effect, blocking the normal function of insulin. As the gestational period goes on, the 
placenta grows, produces more hormones, and the increase of insulin resistance becomes 
greater. Under normal circumstances, and normal pancreatic function, there would 
simply be an increase in insulin production to compensate for the state of insulin 
resistance. However, when the production of insulin is somehow blocked by the effect 
of the placental hormones, GDM can occur. GDM occurs in up to 20% of all pregnancy 
globally, depending on country, population demographic and lifestyle, though 
approximately 30-40% requiring pharmacological treatment. 
27, 28, 29, 30
  
Type II and GDM are characterized by insulin resistance and a subsequent insulin 
deficiency, and numerous studies have demonstrated that the rate of occurrence within a 
population of GDM to Type II Diabetes are similar. 
31
 However, the one real difference 
between Type II and GDM is that pregnancy is a state of increasing insulin resistance, as 
the need to provide a constant supply of nutrients to the fetus. This pathological increase 
in insulin resistance, diminished sensitivity and impaired insulin secretion due to various 
conditions of pregnancy, which runs counter to the need of the developing fetus and 
produces a serious condition of hyperglycemia in the mother. 
32
 So, the goal of any 
Diabetes-related management during pregnancy is to maintain blood glucose as close to 
normal as possible.  
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CHALLENGES OF GDM TREATMENT TO MOTHER AND FETUS  
As noted, GDM occurs in a significant number of pregnancies globally, and is 
considered a risk factor for Type II Diabetes for the mother. There is a great deal of 
evidence that proves the treatment of GDM is far better than not treating GDM. In fact, 
common conditions are drastically reduced through treatment options, saving the mother 
and fetus from hypertension, preeclampsia, urinary tract infections, development of 
Type II diabetes later in life in mothers and child, as well as macrosomia, neonatal 
hypoglycemia, and childhood obesity. 
33
 Leaving these conditions untreated will 
potentially cause harm to the mother and fetus, and requires chronic maintenance 
through proper diet, exercise and pharmacological treatment. 
34
 
Therefore, to be a successful medication for GDM, the need to control blood glucose in 
a similar manner to insulin, while maintaining the safety of the mother and fetus 
paramount. Prescribing drugs in pregnancy represents an unusual situation that must be 
constantly monitored. Drugs that will help the mother can deform or kill the fetus. 
35
  
This is well characterized that there are a small group of drugs that are known to cause 
adverse events or birth defects in humans, but the safety or harm to the fetus must not be 
exaggerated. Today, the importance of monitoring the pregnant woman and fetus for 
harm is well understood, but initially, the placenta was thought to be a barrier, protecting 
the fetus from harm and the mother’s blood, and delivering only what’s needed, for 
example essential nutrients.  The Thalidomide disaster of the 1950’s demonstrated that 
the placenta was a very leaky barrier, and that precautions must be taken when treating 
pregnant women with medicines, as it is now understood that many substances will cross 
the placenta. 
36
 Treatment conditions of the mother quickly accounts for how much harm 
10 
 
will be done to the fetus, and that can be determined by the rate and extent of the of the 
drug concentration that crosses the placenta, and at what gestational stage. 
37
 
For those patients that cannot manage the hyperglycemia with diet and exercise alone, 
the preferred pharmacological treatment option for diabetes has been insulin. The same 
approach is taken for GDM, with insulin as the first line of treatment due to its high 
efficacy, safety, and the fact that the higher molecular weight insulin cannot cross the 
placenta barrier. 
38, 39
 Insulin treatment however, suffers from compliance issues and in 
some countries the cost is prohibitive. 
40
 Specific to pregnant women, the insulin route 
of administration and the schedule of treatments present numerous difficulties.
41
 Due to 
the similarities in GDM and Type II conditions, and the ease of treatment for oral 
medications, doctors have explored treating GDM with the small molecule 
sulfonylureas. 
42, 43
  
In order for the sulfonylureas to be effective in the treatment of diabetes, the patient 
needs to have retained some level of pancreatic insulin-releasing function. 
44
 This holds 
true for GDM based on the similarities of the pathophysiology with Type II, the 
sulfonylurea compounds are an excellent choice for treating either condition. 
45,46
 In fact, 
there is a growing acceptance of Glyburide as a treatment option for GDM, based on the 
attractive pharmacological response and low potential adverse side effects (i.e., neonatal 
hypoglycemia), making the sulfonylurea(s) a viable option based on compliance, and 
overall mother and fetal outcomes. 
47,48, 49
   
Considerable data exists suggesting that Glyburide is a safe alternative to insulin for 
treatment of GDM. 
50
 Numerous clinical studies, and five retrospective studies, have 
been performed on thousands of pregnant women who were taking Glyburide. These 
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studies have been performed to understand the pharmacokinetics and 
pharmacodynamics of Glyburide during pregnancy, and many interesting results have 
been demonstrated. In these multiple, large, randomly controlled clinical studies, 
Glyburide has been shown to be as safe and effective as insulin in pregnant women. 
51, 52, 
53, 54, 55
  Further, placental drug transport studies have demonstrated two key findings: 
Glyburide does not cross the placenta to any appreciable extent, and Glyburide will 
leave the placental barrier against the concentration gradient.
 56, 57, 58, 59, 60 
This represents 
an ideal situation for treating pregnant women and has garnered much excitement.  
 
TRANSPORTER STORY 
The placental transport studies have demonstrated that Glyburide is a substrate for active 
transport by the ATP Binding Cassette (ABC) transporter proteins specifically P-
glycoprotein (Pgp), Breast Cancer Resistance Protein (BCRP), and the Multiple 
Resistance Protein (MRP) family. 
61, 62,63,
 
64
, 
65
 The ABC transporter proteins are part of 
a larger class of drug transporters, with a primary function to transport nutrients and 
endogenous substrates (sugars, amino acids, vitamins), and to protect the body from 
dietary and environmental toxins. 
66
 As the transporters are designed to transport 
substrates of a wide physiologic background, drugs that are similar in structure to the 
physiological substrate can also be transported. It is in this functionality and the ability 
to transport a broad range of substrates that the drug transporters play a significant role 
in the bioavailability, efficacy and PK of most drugs. 
67
 
Transport of drugs can be classified in a variety of ways, with the main characterizations 
being directional (efflux vs influx), and through energy vs non-energy dependent (active 
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or passive) means. For the context of the work reported here, we will focus on the efflux 
by active transport systems, which have been further classified into two main categories, 
primary and secondary. The primary systems utilize ATP hydrolysis to drive the 
transport and include the ABC transporters. The secondary systems are ones that utilize 
multiple driving forces such as ion concertation gradients, and electric potential 
difference across the cell membrane, an example is the Solute Carrier transporters 
(SLC). 
68, 69
 
The ABC proteins of the human genome comprise a family of 49 proteins, and based on 
their amino acid sequence, are divided into roughly 7 sub-families.  As ABC 
transporters serve a protection function, they are found in most tissues at barrier 
locations throughout the body, such as brain, testes, heart, liver, kidney, and 
gastrointestinal tract. Transporter proteins are membrane-bound proteins whose primary 
function is to facilitate the flux of molecules in and out of cells, protecting from toxins. 
70,71, 72
 The ABC drug transporters have a diverse substrate pool; as such, many 
molecules that bear structural similarities to the endogenous compounds may be 
recognized and transported. This diverse set of substrates covers molecules that are 
nonpolar, weakly amphiphilic, and encompass a diverse group of compounds from anti-
cancer drugs to natural products. 
73, 74, 75
  
As illustrated in Figure 4, all ABC Transporter proteins share similar structural 
components, consisting of 4 different domains: two transmembrane and two cytosolic 
domains. The transmembrane domains (TMD) consist of alpha helices (in groups of 5-6) 
embedded in the membrane bilayer, with the ability to recognize and transport a broad 
range of substrates by changing conformations.  The nucleoside binding domains (NBD) 
13 
 
is the location of the binding of ATP that drives the transport mechanism, containing the 
Walker A and B motifs for this function. 
76
  A complete transporter structure is 
considered a homo-dimer or a fully functional transporter, example of which are Pgp, 
MRP, and OATP. The exception to this requires the two smaller monomer structures to 
pair together to form a homodimer, an example of this is BCRP.   
 
 
 
 
 
 
 
 
 
Figure 6. Structures of two categories of ABC transporters, Pgp (ABCB1-MDR1) and 
MRPs are shown on top, BCRP (ABCG2) shown on bottom. 
77
 
 
PROBLEM STATEMENT AND SUMMARY OF REMAINING SECTIONS OF 
THESIS 
 
The ABC transporters described above in Figure 6 hold the key to the unique placental 
transport of Glyburide. As discussed, the oral hypoglycemic sulfonylurea molecule 
Glyburide has been shown to be actively transported through a pronounced interaction 
with the ATP binding cassette (ABC) active transporter proteins. This unique placental 
transport behavior is largely due to the primary transport resulting in the efflux of 
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Glyburide by Pgp and BCRP, minimizing the effect of the drug on the fetus. 
Specifically, the small molecule Glyburide has been shown to not cross the placental 
barrier to any appreciable effect; and, Glyburide will leave the fetal compartment against 
the concentration gradient (active efflux). 
78
  The research presented here will focus on 
understanding this unique placental transport to design medications for pregnant women 
that are safe and effective, without presenting harm to the mother or fetus. 
There is a great deal of research detailing the mechanism of action of the sulfonylureas, 
the PK/PD of the sulfonylureas during pregnancy, and even the specific ABC transporter 
proteins responsible for the unique placental transport behavior. However, there has 
been no research to date to explain the nature of the interaction with the ABC transporter 
proteins to better design pregnancy centered drugs. The research presented here will 
look to explain the interactions of a series of sulfonylurea analogs and two of the main 
ABC proteins responsible for active drug transport, BCRP and Pgp. The work described 
in this body of work was performed in cell-based transport assays using cell lines that 
overexpress Pgp or BCRP, and molecular modeling software packages to build structure 
activity models based on the transport activity. 
In the coming chapters we will explore the interaction of the sulfonylureas with the two 
transporters, individually, building quantitative structure activity relationships (QSAR), 
and then complete the body of work with molecular modeling highlighting the molecular 
descriptors/features that drive the affinity to one transporter or the other. In Chapter 2 
we will evaluate the sulfonylurea analogs using Madin-Darby Kidney Cells (MDCK) 
that overexpress Pgp and BCRP proteins, ultimately building 2D, 3D-QSAR and 
pharmacophore models using the molecular dynamics modeling software VLifeMDS® 
15 
 
to explain the molecule-protein interaction. And finally, in Chapter 3, we will detail and 
explain the similarities and differences between the two molecule-protein interactions, 
using the molecular modeling software Cresset Group Forge®.  The outcome of this 
research will be to characterize the molecular features driving the interactions with the 
ABC transporter proteins, in the hope that this knowledge will help design novel 
pregnancy centered medications.  
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Quantitative Structure Activity Relationship for a Series of Sulfonylurea Analogs 
and two ATP Binding Cassette Proteins, P-glycoprotein and Breast Cancer 
Resistance Protein 
 
ABSTRACT 
Sulfonylureas used in the treatment of Type II diabetes have been shown to interact with 
the ATP binding cassette (ABC) active transporters, P-glycoprotein (Pgp) and Breast 
Cancer Resistance Protein (BCRP). Starting from a series of sulfonylurea compounds, 
two and three-dimensional quantitative structure activity relationship (QSAR) studies 
were performed to determine the essential molecular features responsible for the Pgp and 
BCRP mediated transport. For the both the 2D and 3D QSARs, numerous models were 
developed and evaluated in an effort to correlate the physico-chemical features of the 
sulfonylureas with the biological interaction with Pgp or BCRP. In our studies, the 2D 
Pgp QSAR model with the best prediction capability was found to be a k-Nearest 
Neighbor (kNN) model for substrate activity with a q
2
 = 0.7152, and a r
2
 = 0.8150. For 
the 3D Pgp QSAR model with the best prediction capability, a multiple regression model 
for substrate activity performed best, with an r
2
 = 0.8304, a cross-validation q
2
 = 0.7501. 
In contrast, the 2D BCRP QSAR model with the best prediction capability was a multiple 
linear regression (MLR) model for substrate activity with a q
2
 = 0.8690, and a r
2
 = 
0.8131. Similarly, the 3D BCRP QSAR model with the best prediction capability was a 
multiple regression model for substrate activity with an r
2
 = 0.9063, a cross-validation q
2
 
= 0.7789. All models were cross validated with an autonomous set of compounds not 
used in the training or test sets.  
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As previously reported, Glyburide has been shown to be a substrate for numerous ABC 
transporters, but this is the first comprehensive QSAR study designed to understand the 
interaction driving the active transport of the entire class of sulfonylureas specifically 
with the two ABC transporters, Pgp and BCRP. The physico-chemical properties and 
molecular descriptors of the sulfonylureas were used to build three-dimensional 
pharmacophores to further understand the interactions with Pgp and BCRP. Each 
pharmacophore model contained five features found to be essential for identification as a 
Pgp or BCRP substrate: one hydrogen bond donor, two hydrogen bond acceptors, and 
two aromatic rings. For both Pgp and BCRP pharmacophores, the active sites focused on 
the benzamido and arylsulfonylurea ligands. However, the two pharmacophore models 
differed in the location of the fifth active site, with Pgp activity needing an unsubstituted, 
and the BCRP activity needing the substituted, benzamido ligand. This work confirms 
Glyburide as a substrate for both Pgp and BCRP, and details the oral hypoglycemic 
agents Glimepiride, Glisoxepide, and Gliquidone as Pgp substrates; with Glimepiride and 
Glisoxepide confirmed as BCRP substrates not previously reported.  
 
INTRODUCTION 
The oral hypoglycemic sulfonylurea molecule Glyburide has been shown to be actively 
transported from various biological tissues though a pronounced interaction with the ATP 
binding cassette (ABC) active transporter proteins.  
79, 80, 81, 82, 83, 84, 85 
 Specifically, 
Glyburide is actively transported by the ABC proteins, P-glycoprotein (Pgp), Breast 
Cancer Resistance Protein (BCRP), and the Multidrug Resistance Proteins (MRP). 
86, 87 
This active transport occurs at various locations throughout the body but has been 
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identified as responsible for unique transport behavior of Glyburide at the placenta 
barrier. Glyburide has been shown to not cross the placental barrier to any appreciable 
effect, and will leave the placental barrier against the concentration gradient, attributed to 
the active transport by the ABC proteins. Harnessing the unique placental transfer by the 
ABC proteins and understanding what molecular features drive the drug-protein 
interaction, creates the possibility of designing medications specifically for pregnant 
women. Glyburide is a second-generation sulfonylurea hypoglycemic agent, widely used 
in the treatment of Type II diabetes. 
88, 89, 90
 The sulfonylurea molecule class are insulin 
secratogues, stimulating the ATP sensitive Potassium (KATP) channels within the 
pancreatic β-islet cells. 91 Stimulation of the KATP channel triggers the insulin release via 
the occupation of the ABC sulfonylurea receptor (SUR1) in the β-cell membrane. 92, 93  In 
order for this mechanism to work, patients need to have retained some level of pancreatic 
β-cell function, as shown in the cascade of events presented in Figure 7. 
 
 
 
 
 
 
 
 
Figure 7. Modulation of insulin, reproduced from Tahrani et al. 
94
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In general terms, Type II Diabetes is primarily a condition of progressively impaired 
glucose regulation due to the dysfunction of the pancreatic beta cells and general insulin 
resistance. 
15, 95 
This impaired glucose regulation can also occur in pregnant women and 
is commonly referred to as pregnancy induced gestational diabetes mellitus (GDM). 
GDM occurs in up to 20% of all pregnancy globally, with approximately 90% of those 
diagnosed as treatable Type II diabetes, and roughly 30-40% requiring pharmacological 
treatment. 
4, 96, 97, 98
  
 
                                                           
                                                                                           
 
Figure 8. Structures of the Glyburide and the sulfonylurea backbone. 
 
For both Type II and GDM, insulin has been the gold standard of treatment; however, 
with the availability and ease of treatment of oral hypoglycemic medications, doctors 
have recently attempted to treat GDM with small molecule therapeutics.
 99,
 
100, 101
  The 
similarities of the pathophysiology of both the Type II and GDM indicate that the oral 
hypoglycemic sulfonylureas are appropriate, and numerous studies have been performed 
to understand the pharmacokinetics and pharmacodynamics of Glyburide during 
pregnancy. 
1, 16
 In multiple clinical studies, Glyburide has been shown to be as safe and 
effective as insulin in pregnant women. 
102, 103, 104, 105, 106
  Further, studies evaluating the 
fetal pharmacokinetics of Glyburide have demonstrated two remarkable findings: that 
Glyburide does not cross the placenta to any appreciable extent as compared to other 
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sulfonylureas (Glyburide 3.9%, Glipizide 6.6%, Tolbutamide 21.5%, and 
Chlorpropamide 11%) and Glyburide will leave the placenta barrier against the 
concentration gradient.
107
 As previously mentioned, this unique placental transport 
behavior has been demonstrated to be ABC transporter mediated. Evaluation of this 
unique transport has been performed in vitro, and repeatedly demonstrated in cell lines 
and in placenta-like models (vesicles, perfused placenta, etc.), confirming Glyburide as a 
substrate for active transport, and demonstrating that the mechanism of placenta transport 
can be studied in vitro.
108, 109, 110,111
 
Understanding the sulfonylurea and ABC transporter interactions and the unique 
placental transport serves as an example for the design of pregnancy center drugs. To 
further investigate this unique interaction of the sulfonylureas with the ABC transporter 
proteins, Glyburide and a series of sulfonylurea analogs were tested in in vitro cell-based 
transport assays using a Madin-Darby kidney cell (MDCK) lines overexpressing either 
the Pgp or BCRP proteins. From the measured transporter activity, we developed both 2D 
and 3D quantitative structure activity relationship (QSAR) models to account for the Pgp 
and BCRP substrate activity for the sulfonylurea compounds. To accompany this work, 
we have performed a two-step computational study to generate the 3D pharmacophore to 
aid in describing the parts of the molecule responsible for the Pgp and/or BCRP activity. 
 
MATERIALS and METHODS  
A set of 78 sulfonylurea compounds were acquired for this study, selected via a 
compound similarity search against Glyburide in both the Pfizer internal and publicly 
available external databases. The compounds for the study were further selected based on 
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the Tanimoto searching criteria of >70% similarity, which allowed for the selection of 
molecules based on the structural similarities to Glyburide. The sulfonylurea analogs 
were divided into two groups, the commercial sulfonylureas (molecules 1-14) and the 
sulfonylurea analog series (molecules 15-78). The structures of all molecules studied are 
presented in Appendix I and II.  
 
CELL CULTURES  
The Madin-Darby Canine Kidney cell line stably transfected with the Pgp gene (MDCK-
MDR) or the BCRP gene (MDCK-BCRP) were used in the present study and have been 
thoroughly characterized. 
112,113, 114
 The MDCK-MDR cells were initially received from 
Pier Borst and the National Cancer Institute (NCI), Netherlands, and maintained by the 
PDM labs, Pfizer Global Research and Development, Groton, CT. 
115, 116, 117, 118
  The 
MDCK-BCRP cell line are a stably transfected cell line, developed and maintained at the 
Pfizer PDM labs Groton CT. 
119
 Briefly, the stably transfected MDCK-MDR or MDCK-
BCRP cells were cultured in Dulbecco’s minimum essential media (MEM) with 
supplements, in 75cm
2
 tissue culture T-flasks were incubated at 37°C with 95% and 5% 
CO2 and passaged every 4 days after achieving 90% confluence. The cells were then 
harvested with trypsin and plated for a density of 2 x 10
6 
cells/cm in Falcon/BD 96 well 
insert plates with a 1µm pore polyethylene terephthalate filter. Seeded inserts were then 
placed into prefilled Falcon/BD feeder trays containing 37mL growth medium and 
incubated at 37°C with 95% and 5% CO2 for 4 days. Immediately prior to performing the 
assay, each well of the plates were assessed for uniform barrier functionality of the 
polarized cell monolayers. The integrity of the MDCK-MDR or MDCK-BCRP cell 
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monolayers were evaluated by measuring the trans-epithelial electrical resistance, and 
only those cell monolayers with a measurement with of at least 320Ωcm2 were used.120 
 
TRANSPORT ASSAY PROCEDURES 
The cell transport assays are the most direct assay for performing drug transfer studies 
across a cell monolayer, and to determine a transporters function. The transport assays 
have been standardized in that the cell lines are widely shared between research labs or 
are commercially available. All transport assays were performed as per standard 
procedures, and as previously described. 
121,122, 123, 124
 Briefly, the assays were performed 
in Hanks’ balanced salt solution with 10mM HEPES and 25mM D-glucose, 1.25mM 
CaCl2, and 0.5mM MgCl2 at pH 7.4. Assays were performed with set drug concentrations 
(2-100µM) and performed in triplicate to generate statistically sound data. Transport 
studies were performed by adding the compounds pre-dissolved in dimethyl sulfoxide 
(DMSO)/transport buffer to the donor wells and measuring the appearance of drug in the 
receiver wells after 2.5 hours at 37°C. For all of the transport studies performed, the drug 
was added to the donor compartment A, or the apical side. And the analysis was 
completed by measuring the compartment A concentration against the receiver 
compartment B, or the basolateral side. Figure 9 depicts an example insert and transport 
directions used in the present study. 
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  Figure 9. Typical cell monolayer setup for Pgp and BCRP assays. 
 
LC-MS ANALYSIS 
The LC-MS analysis was conducted according to internal procedures, and as previously 
described by L. Di et al, Feng et al, and Varma et al. 
 125, 126 ,127 
Briefly, samples of 25µL 
were injected on a Sciex API-5500-Electrospray LC system comprising an Optimize 
Technologies SP Small Molecule Trap column, an Apricot/Sounds Analytics ADDA 
autosampler, Jackso PU-1580 HPLC pump, and a quadrapole MS detector using the 
multiple reaction monitoring (MRM) detection mode. Mobile phase A was 95% 2mM 
ammonium acetate/5% 50/50 acetonitrile/methanol and mobile phase B was 90% 50/50 
acetonitrile/methanol/ 10% 2 mM ammonium acetate, at a flow rate of 1.5mL/min. The 
AUC was integrated using Analyst 1.5.1/DiscoveryQuantAnalyze software, version 
2.1.0.14 and compared to standards for each compound in cell culture media for the 
quantification of concentrations. 
 
DATA ANALYSIS 
For these studies, the apparent permeability (Papp) was calculated for each compound 
according to equation 1: 
 
MDR 
B 
A A 
B 
Uptake Efflux 
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       Equation 1 
 
Where the area is the surface area of the cell monolayer (0.625cm
2
), CD (0) is the 
concentration of compound in the donor chamber, t is the time, Mt is the mass of the 
compound, and  is the flux of compound across the cell monolayer.  The Papp was 
calculated in both apical to basolateral and basolateral to apical directions to determine 
the efflux ratio as shown in Equation 2. 
 
                                               Equation 2 
 
where A→B and B→A denote the direction of transport. In order for a compound to be 
characterized as a Pgp substrate, the value of the efflux ratio (ER) would exceed a value 
of 2.5. The value of 2.5 was determined through internal data analysis and has been 
demonstrated to minimize the false-positive and false-negative results in the assay as 
tested by the appropriate internal control molecules for each cell line. The efflux ratio is a 
way to rank order and predict ABC transporter activity, with the larger efflux ratio 
meaning substrate activity. 
 
CELL ASSAY MATERIALS  
The 14 commercial sulfonylureas (molecules 1-14 in Appendix 1) were purchased from 
Sigma Aldrich, WI, or donated from Pfizer Global R&D, Groton CT. The sulfonylurea 
analogs (molecules 15-78 in Appendix I and II) were donated from Pfizer Global R&D, 
26 
 
Groton CT. Cell culture media reagents, transport buffer (including Hanks balanced salt 
solution, HEPES, d-glucose, 1.25mM CaCl2 and 0.5mM MgCl2) were purchased from 
Invitrogen, Carlsbad CA. All organic solvents were purchased from Sigma Aldrich, WI 
and used as is.   
 
COMPUTER MODELING 
All computational studies were performed on an HP, Intel i5 processor running Windows 
7 Professional Office, with VLifeMDS® software (version 4.6). 
128
 In order to minimize 
variability and difficulty interpreting the results, it is important to establish a statistically 
significant correlation between the molecular descriptors and the biological activity. This 
correlation starts with the molecular alignment of the molecules across the test, training, 
and validation data sets. 
129 
 Due to the well documented Glyburide ABC substrate 
activity, and the common sulfonylurea backbone of the molecules in the present study, 
Glyburide was used as the template molecule. 
As the x-ray crystal structures of the compounds or the ABC transporter proteins were 
not available, the 2D structures were obtained from Chemaxon® Marvin Sketch and 
ChemDraw® 15.1. 
130, 131
 The sulfonylurea molecules are all flexible with many rotatable 
bonds which required energy minimization prior to modeling. The minimization was 
carried out in the ChemDraw® 3D 15.1 suite utilizing the Merck Molecular force field 
(MMFF94). 
132, 133, 134, 135
  The energy minimizations were carried out using 1000 
iterations to eliminate any change in conformations. The RMS gradient was set to 0.100, 
the dielectric constant was set to 1.0 and exact calculation, and the Van der Waals 
calculation was set to exact. To maximize the modeling, 1000 calculations were 
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performed to eliminate any variability in the lowest energy conformations. The RMS and 
van der Waals calculations are parameters that can be adjusted to enhance the threshold 
interactions. For our modeling efforts described here, the RMS and van der Waals 
parameters were left as recommended by the software. The Figure 4 shows the overlay of 
the MMFF94 energy minimized molecules. 
The total energy of the molecular conformation was calculated using the MMFF94 
relationship presented in Equation 3: 
 
   Etotal = EB + EA + EBA + EOOP + ET + EvdW + Eelec                      Equation 3 
where, 
EB = bond stretching energy 
EA = angle bending energy 
EBA = bond stretching and angle bending energy 
EOOP = out of plane bending energy 
ET = torsion energy 
EvdW = van der Waals energy 
EELEC = electrostatic energy 
 
 
As shown in the energy equation, the MMFF94 energy calculation has multiple energy 
terms to capture all potential molecular motions. The total energy of the system is 
calculated as the sum of individual energy terms defined for a force field. 
136
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            Figure 10. Molecular Overlay of MMFF94 energy minimized molecules. 
 
After energy minimization, the molecules were loaded into the VLifeMDS® software 
and aligned to a set conformation using the VLifeEngine® module. To correctly overlay 
the molecules for quality QSAR modeling, the alignment was performed using the 
modules’ atom-based approach. This approach allowed for the selection of the central 
arylsulfonylurea section of the Glyburide template molecule.   Figure 9 depicts the 
molecule overlay of the energy minimized molecules, with Figure 11 showing the 
sulfonylurea backbone chosen for molecule conformer alignment template (highlighted in 
red). 
 
 
 
 
Figure 11.  Glyburide molecule with the sulfonylurea backbone template (highlighted in 
red). 
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As mentioned previously, with not all crystal structures of the compounds available, the 
lowest energy conformations were calculated for each compound using ChemDraw® 
15.1. Yuriev et al evaluated previous glyburide structure analysis and modeled glyburide 
to determine the three-relevant energy minimized structures - crystal, in vacuo, and in 
solution. 
137
 Previous work L. Lin et al, S.R. Byrn et al, W. Grell et al, and T.J. Hou 
explain the various Glyburide energy minimization work in detail. 
138, 139,
 
140,
 
141
 In 
summary, the Glyburide SD file was loaded into ChemDraw, and the MMFF94 energy 
minimization calculations were performed as described. The Lin et al published lowest 
energy confirmations for Glyburide in solution was chosen as the most representative 
conformation for our studies. 
These findings demonstrate the viability of energy minimization modeling in absence of 
crystal structures. The MMFF94 energy minimization for the sulfonylurea analogs 
matched the Lin low energy solution model very closely and was used in the present 
study, as presented in Figure 12. Future work will evaluate different energy 
minimizations and docking, and how that influences the QSAR modeling.  
 
 
 
 
      
   
         Figure 12. Energy minimized MMFF94 structure of Glyburide. 
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EXPERIMENTAL 
The experimental work was divided into two main sections, (1) assessing the commercial 
sulfonylureas as Pgp or BCRP substrates, and (2) then screening a large series of analogs 
for activity to better understand the molecular features responsible for the Pgp or BCRP 
activity.  The initial experiments were designed to determine if any of the 14 commercial 
sulfonylureas (shown in Figure 1) demonstrated Pgp or BCRP activity, and to what 
extent. The second set of experiments reported here was designed to determine the two 
and three dimensional molecular descriptors of a series of sulfonylurea analogs 
responsible for the Pgp or BCRP transporter activity. The molecular descriptors are 
described in Appendix IV. 
The initial evaluation of the commercial sulfonylureas was run at a standard 
concentration, and all compounds were run in at least triplicate. Traditionally, transport 
assays evaluating the sulfonylureas have been performed with concentrations ranging 
from 1-500µM, depending on the substrate or inhibitor function.
142
  Accounting for this 
range, our studies were performed at a nominal concentration of 2 µM for the 
sulfonylurea analogs due to ease of screening and to not saturate the transport mechanism 
for Pgp or BCRP activity.  Also, to make sure our cell monolayers were performing as 
expected, compounds with well documented Pgp or BCRP activity were used as the 
controls. The negative control was the molecule antipyrine, which demonstrates unilateral 
crossing of the MDCK-MDR and MDCK-BCRP cell monolayers (antipyrine efflux ratio 
= 0.99); the positive control for the MDCK-MDR cells was vinblastine which is a well-
documented substrate/inhibitor of Pgp (vinblastine efflux ratio =6.42); and the positive 
control for the MDCK-BCRP cells was novobiocin which is a well-documented 
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substrate/inhibitor of Pgp (novobiocin efflux ratio =8.65).
 
From this group of commercial 
sulfonylureas, four molecules demonstrated high Pgp substrate activity (Glyburide, 
Glimepiride, Glisoxepide, and Gliquidone), and one molecule was borderline (Glipizide). 
Only three of these molecules demonstrated BCRP substrate activity (Glyburide, 
Glimepiride, and Glisoxepide). These molecules are similar to Glyburide, and are also 
second-generation sulfonylureas, exhibiting a better safety profile, increased potency, and 
higher binding affinity to the Sulfonylurea 1 (SUR1) protein. 
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Having determined the Pgp activity of the commercial sulfonylureas, the next step of the 
evaluation was to test the various concentrations of the four compounds to confirm Pgp 
activity as a function of the concentration. Glyburide, Glimepiride, Glisoxepide, and 
Gliquidone were dosed over a concentration range of 2-100 µM. As Glipizide did not 
show Pgp activity in the initial screening study, it was not included in the second round 
of testing. Compared to therapeutic doses of Glyburide of approximately 0.202 µM, this 
concentration range represents an approximately 10-500 times increase in concentration 
and is used to ensure a reproducible measurement.  All four compounds demonstrated an 
asymmetric transport across the concentration range, with the absorption of each 
compound increased with concentration, whereas the efflux slightly increased with 
increasing concentrations. Figure 13 depicts the asymmetric relationship of Glyburide, 
Glimepiride, Glisoxepide, and Gliquidone. 
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Figure 13. Bar graphs showing asymmetric absorption and efflux of Glyburide, 
Glimepiride, Gliquidone, and Glisoxepide. Note: A denotes A-B transport; B denotes B-A 
transport.  
 
As shown in the bar graphs of Figure 13, the lower concentrations of the compounds 
demonstrated the active transport out of the cells from the basolateral to apical. In the 
lower concentration ranges (2-20 µM) the rate of efflux exceeded the rate of absorption 
by the following values: approximately 6-8 times for Glyburide, 5-6 times for 
Glimepiride, 3-4 times for Gliquidone, and 5-7 times for Glisoxepide. At the highest 
concentration tested (100µM), the transport was nonlinear, and the transport started to 
balance out, especially for the Glyburide assay. This is an effect of the inhibitory nature 
of the compounds at the 100µM concentration, as discussed in literature. 
144
 These 
findings demonstrate the transport is a carrier mediated process from the basolateral to 
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apical compartment for each of the compounds represented. These results were expected 
based on the known Pgp-Glyburide interaction, and the molecular similarities of the four 
compounds. Also, the non-Pgp activity of Gliclazide was expected as the only reported 
Gliclazide Pgp activity found in literature was at very high concentrations. 
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The bulk of the experimental work reported in this paper was performed to evaluate a 
large series of sulfonylurea analogs as substrates of the ABC transporters (Pgp and/or 
BCRP), and to use this information to build 2D and 3D QSAR models. Based on the 
initial experiments, and internal procedures, all the sulfonylurea analogs cell transport 
assays were performed at 2µM and measured in triplicate. It is well understood that the 
work reported describes local models for both Pgp and BCRP, as all the compounds used 
in the study were sulfonylureas, though containing structurally diverse R1 and R2 groups 
(described in Appendix I). However, even though structurally similar, the 78 sulfonylurea 
analogs spanned approximately 3 logs of Pgp activity and 2 logs of BCRP activity, as 
shown in Figures 14 and 15. 
 
 
Figure 14. Map of all 78 compounds and the respective log Papp activity. Note: red 
dotted line represents the activity cutoff value of 0.4 (ER value =2.5).  
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Figure 15. Map of all 53 compounds and the respective log BCRP Papp activity. Note: red 
dotted line represents the activity cutoff value of 0.4(ER value =2.5.  
 
The compound activity maps in Figures 13 and 14 represent the range of activities for the 
molecules used in our research. As you can see, the log normalized range of activity for 
all of the compounds was between -0.5 to 2.0. Based on the cutoff values from both of 
the transport assays of 2.5 for substrate activity, the cutoff for activity is 0.40 as shown 
by the red dotted line in both Figures 13 and 14. The log scale of the activities represents 
the activity values from 0 to 56, with negative numbers simply representing the log 
calculations of activities less than 1. 
 
MATHEMATICAL MODELS 
Molecular dynamics modeling was performed using the VLifeMDS®, version 4.6 
software package to evaluate the physico-chemical properties of sulfonylurea molecules 
against the biological activity of Pgp efflux. The basic assumption of QSAR and 
molecular modeling is that the interactions of the aligned molecules to a probe or model 
molecule will provide the necessary features to explain the biological activity. The most 
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important assumption then, is that any change in biological activity is directly related to 
the changes in the molecular properties.  The VlifeMDS® software package has multiple 
modeling algorithms available, but only the models used in the present study will be 
discussed and explained in more detail here. However, the available modeling algorithms 
in the VLifeMDS software package are nearest neighbor (kNN), partial least squares 
regression (PLSR), and multiple linear regression (MLR), techniques. An initial 
screening of the activity data and each model was performed to determine the best 
statistical modeling algorithm to use for our research. For the Pgp work, the kNN and 
MLR demonstrated the best model predictions for the 2D and 3D QSAR, respectively. 
For the BCRP work, the MLR demonstrated the best model predictions for both the 2D 
and 3D QSAR. 
Developing QSAR models is an iterative approach, and hundreds of modeling 
simulations were performed to evaluate the necessary parameters and build the most 
representative models defining each sulfonylurea and ABC transporter activity. The 
models presented here represent the most appropriate to define the sulfonylurea-protein 
interactions, and the most predictive, and will be discussed individually here. 
 
QSAR DISCUSSION 
A QSAR model is a regression or classification model that relates a set of predictor 
variables (x) to the potency of a response variable (y). The QSAR model is defined by the 
two and three-dimensional descriptors that make up the space surrounding the molecule, 
and are important tools to describe the correlation of a biological activity to the molecular 
features responsible for the activity. To explain the interaction of the sulfonylureas with 
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the Pgp and BCRP proteins, we developed both 2D and 3D QSAR models that will be 
described in more depth here. 
The 2D QSAR models require calculating molecular descriptors and matching the 
molecular descriptors to a biological activity. The 2D modeling and descriptors are the 
most widely used, based on their simple nature of employing a direct math algorithm that 
is highly reproducible and requires minimal compute time consumption. 
146
 In contrast, 
the 3D QSAR models are more in-depth and require more computational time to 
complete the analysis. In the VLifeMDS® software, there are approximately 1300 
molecular descriptors used for the 2D QSAR models, whereas the 3D QSAR models use 
steric (S) and electrostatic (E) descriptors that specify the region where the structural 
feature variation between the test and training set of compounds leads to an increase or 
decrease in activity.
147
 VLifeMDS® comes equipped with numerous statistical modeling 
algorithms for both 2D and 3D QSAR modeling, including partial least squares (PLS), k-
nearest neighbor (kNN), and multiple linear regression (MLR). All modeling studies 
were performed with the stepwise forward and backward variable selection methods 
which resulted in hundreds of models in 2D and 3D space for each protein. The stepwise 
forward and backward variable selection is a technique of choosing the predictive 
variables that are carried out by the software. The fundamental difference between the 
forward and backward selection methods is the use of descriptors (backward) or no 
descriptors (forward) to build the model. 
148
 The Pgp and BCRP models with the greatest 
predictive ability were achieved with MLR or kNN regression analysis and will be 
described here in more depth. 
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The kNN method adopts a nearest neighbor principle for generating the relationship 
between the molecular descriptors and a given biological activity. The basic principle of 
the kNN classification model is that the compounds are assigned to a class membership 
of its nearest neighbors in a common rectangular grid, taking into account the weighted 
similarities between a compound and its nearest neighbors. 
149, 150 
 The kNN statistical 
methodology is represented by points of the grid in the form of  
 
Y = (point) (value) (point1) (value1)                              Equation 4 
 
where: y is the dependent variable (activity), and the points and values represent 
descriptors, or steric/electrostatic spaces on the grid.  
 
Also included in the VLifeMDS® software are numerous regression methods to calculate 
the best for the data, with the Multiple Linear Regression (MLR) methodology 
demonstrated the greatest predictive ability for the sulfonylurea and ABC transporter 
protein interactions.
151
 The MLR methodology relates the dependent variable (activity) to 
a number of independent variables (molecular descriptors) through linear equations. The 
MLR analysis estimates the values of regression by applying least squares curve fitting 
methods. 
152, 153  
The MLR equation takes the form:       
                 
             Y = b1* x1 + b2* x2 + b3*x3 + c                                        Equation 5 
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where: Y is the dependent variable (activity), b’s are the regression coefficients of the 
corresponding x’s (molecular descriptors), and c is the regression constant (intercept).  
Simply stated, the points and values represent molecular descriptors surrounding the 
molecule on the grid in 2-dimensional space or the steric and electrostatic descriptors of 
the 3-dimensional space.  
The predictive ability of the both the 2D and 3D models was evaluated by the cross-
validation (q
2
) term, employing the leave one out (LOO) methodology. The LOO 
principle is a method that computes the statistics for the left-out value, allowing for faster 
computation time.
154,
 
155
 Simply, in the LOO principle, one data point is selected from the 
test set, and the model is built around the remaining points, with the model cross-
validated against the error on the single point held out of the model. This process is then 
repeated for each point of the training set and averaging the results in the final model. 
The leave one out equation is presented as equation 6 here: 
 
                                              Equation 6 
 
The predictive ability of all the QSAR models was confirmed by the predicted r
2
 
(pred_r
2
) and the external validation test data set.  One final point used in the evaluation 
is the standard error of estimation for the cross-validated q
2
 and the predicted r
2
, with a 
low standard error signifying that the models are statistically significant. In summary, the 
VLifeMDS® software program calculates the best model based on the squared 
correlation coefficient (r
2
) which defines the linearity, the cross validated coefficient (q
2
) 
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which is a measure of quality of the fit, and the predicted r
2
 value. The low standard of 
error for each of the terms shows the quality of the fitness of the model, and the Ftest 
values demonstrate the variance due to the error of the models, with high F test values 
indicating that the models are statistically significant.  As there were hundreds of 
modeling attempts made, the q
2
 and pred r
2
 values were the main factors governing the 
selection of the optimal models. 
For the modeling work described here, all models were generated using the 70:20:10 
approximation; 70% of the molecules were used as the training set, 20% as the test set, 
and the remaining 10% as the independent set used for the external validation of the 
model. An important note is that the VLifeMDS® program randomly selects the training, 
test, and independent set molecules for each model built. For all the sulfonylurea-Pgp 
models, this amounted to a training set of 54 compounds, a test set of 15 compounds and 
validated with an independent set of 9 compounds. In comparison, all of the sulfonylurea-
BCRP models used a training set of 38 compounds, a test set of 11 compounds, and 5 
compounds used as the independent set to validate the model. 
 Finally, all the models generated for each protein in both the 2D and 3D space were 
evaluated for acceptable performance against linearity, cross-validation, standard error, 
and the predictability of the model to identify substrates not in the training or test set. 
Many models succeeded in one or two of the criteria, but the models chosen to describe 
the behavior had the best balance of high linearity and cross-validation values, low 
standard error, and high ability to predict substrate behavior. 
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Pgp 2D QSAR DISCUSSION 
Of the 200 models run, the optimum model to describe the sulfonylurea-Pgp interaction 
within the 2D space was obtained in Model 58, using the kNN methodology with sphere 
exclusion.
 156
 The sphere exclusion technique represents a simple clustering method 
whereby molecules are clustered together based on a defined similarity score, continuing 
until all molecules are grouped. 
157
 Model 58 parameters are shown in Table 2 and proved 
very robust and an excellent cross validation (q
2
), with the predicted r
2 
and externally 
validated r
2
 very close in value, but not over-predicting. This is an important point as 
over-predicting models can lead to false predictions, allowing the model to incorrectly 
label molecules as substrates/non-substrates for activity. The external predictability of 
Model 58 was determined by the predicted r
2
 (pred_r 
2
) value, which was 0.8150, 
meaning that the model has a prediction rate of 81.5%.  This prediction rate is right in 
line with the observed Pgp activity data for Glyburide, Glimepiride, Glipizide, 
Glisoxepide, and Gliquidone with the model ability to select 4 out of 5 molecules’ 
activity. Table 1 summarizes the kNN QSAR Model 58. 
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Table 1. Statistical results of 2D QSAR kNN Model 58 for the Sulfonylurea-Pgp activity. 
 
Graphing the predicted vs. the experimental Pgp activity is also a good way to assess 
model performance. Model 58 shows good linear correlation between the two data sets, 
as presented in Figure 16. 
 
 
Figure 16. Graphical representation of predicted Pgp activity vs. experimental activity for 
the training and test sets for kNN Model 58. 
 
 
Statistical 
Parameter 
2D kNN QSAR 
Model 58 
n 3 
k 54 
deg. of free
 
46 
q
2 
0.7151 
q
2 
se 0.2536 
Predicted r
2
 0.8150 
Predicted r
2
 se 0.2705 
ext val r
2
 0.8288 
ext val r
2
 se 0.2261 
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Table 2. Molecular Descriptors used in 2D QSAR Study  
Model Molecular 
Descriptor 
Description 
   
58 DipoleMoment DipoleMoment signifies the dipole moment 
calculated from the partial charges of the molecule 
6chaincount 6chaincount signifies the total number of six 
membered rings in a compound 
Chi4 Chi4 signifies atomic valence connectivity index 
(order 4) 
K3alpha K3alpha signifies the third alpha modified shape 
index 
SaaaCcount SaaaCcount signifies the total number of carbons 
connected with three aromatic bonds 
SAMostHydrophobi
c 
SAMostHydrophobicHydrophillicDistance signifies 
the distance between the most hydrophobic and 
hydrophilic point on the vdW surface 
HydrophillicDistanc
e 
HydrophillicDistance signifies the distance between 
the hydrophilic groups on the vdW surface 
SdssS(sulfate)E-
index 
SdssS(sulfate)E-index signifies the electropological 
state indices for the number of sulfate groups 
connected with two single and two double bonds 
 
 
The 2D QSAR model to define the interactions with Pgp had eight 2D contributing 
descriptors. The full description of the 2D descriptors of Model 58 are presented in Table 
1. The eight descriptors used for Model 58 descriptors are DipoleMoment, 6chaincount, 
Chi4, K3alpha, SaaaCcount, SAMostHydrophobic, HydrophillicDistance, and 
SdssS(sulfate)E-index. These molecular descriptors characterize the specific information 
about the sulfonylureas that drive the interaction with Pgp. 
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The 2D equation defining the Pgp and sulfonylurea activity is presented here: 
 
pPgp Efflux = DipoleMoment (5.1080, 5.9350) 6ChainCount (-0.0390, -0.0280) chi4 
(2.0000, 3.0000) k3alpha (8.8890, 9.1500) SaaaCcount (6.4530, 8.1170) 
SAMostHydrophobicHydrophilicDistance (0.0000, 0.0000) SddssS(sulfate)E-index 
(0.0000, 0.0000) 
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Molecule 
Efflux 
Ratio 
logEfflux 
Ratio 
Predicted 
logEfflux 
Ratio  
Residual Molecule 
Efflux 
Ratio 
logEfflux 
Ratio 
Predicted 
logEfflux 
Ratio  
Residual 
1 6.39 0.806 0.959 -0.153 41 1.76 0.246 0.076 0.169 
2 2.75 0.439 0.792 -0.352 42 2.24 0.35 0.397 -0.047 
3 6.21 0.793 0.418 0.375 43 1.52 0.182 0.106 0.076 
4 5.51 0.741 0.898 -0.157 44 1.09 0.037 0.04 -0.003 
5 2.3 0.362 0.458 -0.096 45 1.34 0.127 0.402 -0.275 
6 0.93 -0.032 -0.052 0.02 46 1.54 0.188 0.207 -0.019 
7 0.9 -0.046 -0.596 0.55 47 3.57 0.553 0.37 0.183 
8 0.99 -0.004 0.017 -0.022 48 12.4 1.093 0.695 0.399 
9 0.53 -0.276 -0.13 -0.145 49 3.05 0.484 0.685 -0.201 
10 0.82 -0.086 -0.056 -0.031 50 5.89 0.77 0.275 0.495 
11 0.76 -0.119 -0.13 0.011 51 2.89 0.461 0.627 -0.166 
12 0.7 -0.155 0.138 -0.293 52 4.37 0.64 1.001 -0.36 
13 0.65 -0.187 -0.132 -0.055 53 12.5 1.097 0.967 0.129 
14 0.74 -0.131 -0.114 -0.016 54 9.38 0.972 0.893 0.08 
15 0.55 -0.26 -0.121 -0.139 55 1.36 0.134 0.35 -0.217 
16 0.56 -0.252 -0.124 -0.128 56 57.4 1.759 1.082 0.677 
17 5.4 0.732 0.698 0.034 57 5.35 0.728 0.922 -0.194 
18 10.2 1.009 1.027 -0.018 58 7.64 0.883 1.008 -0.125 
19 4.17 0.62 0.68 -0.06 59 6.7 0.826 0.861 -0.035 
20 2.99 0.476 0.45 0.025 60 16.5 1.217 1.104 0.113 
22 9.3 0.968 0.559 0.41 61 3.62 0.559 0.493 0.066 
23 2.43 0.386 0.551 -0.165 62 3.08 0.489 0.361 0.128 
24 1.33 0.124 0.11 0.013 63 9.74 0.989 0.883 0.106 
25 9.73 0.988 0.72 0.268 64 7.81 0.893 0.941 -0.049 
26 8.45 0.927 0.976 -0.049 65 14.3 1.155 0.94 0.215 
27 3.83 0.583 0.401 0.182 66 11.7 1.068 0.831 0.238 
28 12.8 1.107 1.034 0.073 67 1.72 0.236 0.521 -0.285 
29 5.41 0.733 0.941 -0.208 68 28.4 1.453 1.315 0.138 
30 2.04 0.31 0.636 -0.327 69 25.5 1.407 0.695 0.711 
31 8.52 0.93 0.661 0.269 70 7.45 0.872 0.964 -0.092 
32 12.9 1.111 1.144 -0.033 71 18.1 1.258 1.393 -0.135 
33 21 1.322 1.199 0.123 72 24.3 1.386 1.472 -0.086 
34 15.3 1.185 0.899 0.286 73 1.34 0.127 0.428 -0.301 
35 3.37 0.528 0.362 0.165 74 1.06 0.025 0.469 -0.443 
36 1.56 0.193 0.115 0.078 75 2.93 0.467 0.5 -0.033 
37 5.08 0.706 0.878 -0.172 76 4.29 0.632 0.527 0.106 
38 0.44 -0.354 0.243 -0.596 77 0.85 -0.072 0.699 -0.771 
39 1.62 0.21 -0.064 0.274 78 12.4 1.093 1.098 -0.005 
40 0.68 -0.166 0.314 -0.48 79 6.07 0.783 0.797 -0.014 
  
Table 3 Molecules used in study with experimental, predicted, and residual activity. 
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To further evaluate the model describing the sulfonylurea and Pgp interaction, the nearest 
neighbor algorithm was performed at three, six, or nine nearest neighbors for the 
calculations. Though all the models presented similar results, the kNN models with the 
increased nearest neighbor values did not outperform the simpler Model 58 with only 
three nearest neighbor parameters. In fact, as shown in Table 4, Model 58 with the n = 3 
parameter outperformed the n = 6 and n= 9 nearest neighbor models with better Predicted 
r
2
 and Ext Val r
2
 values, in a head to head comparison. The three most representative 
kNN models using the 3, 6, and 9 nearest neighbors are presented in Table 4 for 
comparison.  
 
Statistical 
Parameter 
2D kNN 
QSAR Model 
58 
2D kNN 
QSAR Model 
31 
2D kNN QSAR 
Model 50 
n 3 6 9 
k 54 54 54 
deg. of free
 
46 48 48 
q
2 
0.7151 0.7306 0.7210 
q
2 
se 0.2536 0.2606 0.2626 
Predicted r
2
 0.8150 0.7961 0.6312 
Predicted r
2
 
se 
0.2705 0.2120 0.3149 
ext val r
2
  0.8288 0.7706 0.7880 
ext val r
2
 se 0.2261 0.2727 0.2472 
 
Table 4. Comparison of the 3-6-9 nearest neighbors Models for Pgp 
 
This was relatively unexpected as usually the more neighbors, the more rigorous the 
calculations due to the larger fields of interaction, and hence a better model. However, 
the structural similarity of the sulfonylurea analogs made the selection of a larger nearest 
neighbor factor an insignificant point. As the longer and more extensive calculations for 
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increased nearest neighbor parameters did not prove to be a better modeling assumption, 
further modeling attempts will be performed as simple as possible, increasing the 
throughput without sacrificing robustness. As you presented in Table 4 above, the nearest 
neighbor calculations for the n = 3, 6, or 9 values were close but turned out to be not that 
as predictive as the Model 58 (n = 3). Comparing the models, we see that the cross 
validation was better in the n = 6 and 9 models (0.7151 to 0.7306 to 0.7210); however, 
the n = 3 model beat the others in both the pred_r
2 
(0.8150 compared to 0.7961 and 
0.6312), and external validation r
2
 (0.8288 compared to 0.7706 and 0.7880). 
 
 
BCRP 2D QSAR DISCUSSION 
The optimum model to describe the sulfonylurea-BCRP interaction within the 2D space 
was obtained in Model 89, using the MLR methodology, with the sphere exclusion 
technique. 
158
 Model 89 parameters are shown in Table 3, proved very robust and an 
excellent cross validation (q
2
), with the predicted r
2 
and externally validated r
2
 also very 
close to in value, but not over-predicting, similar to the model for Pgp. The external 
predictability of Model 89 was determined by the predicted r
2
 (pred_r 
2
) value, which 
was 0.7711, meaning that the model has a prediction rate of 77.11%.  
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Table 5. Statistical results of BCRP 2D QSAR MLR model 
 
As shown in Table 5 above, the MLR Model 89 also proved very robust and 
demonstrated excellent linearity with low standard error.  Model 89 models was very 
accurate, with excellent cross validation (q
2
), with the predicted r
2 
and externally 
validated r
2
 very close in value, but as seen in the Pgp model, also not over-predicting. 
The external predictability of Model 89 was determined by the predicted r
2
 (pred_r 
2
) 
value, which was 0.9185, meaning that Model 89 has an external prediction rate of 
91.85%.   
Graphing the predicted verse the experimental Pgp activity also demonstrated the linear 
correlation between the two and is presented in Figure 17. 
 
 
Statistical 
Parameter 
2D QSAR MLR 
Model 89 
n 38 
deg. of freedom 30 
r
2 
0.8690 
q
2 
0.8131 
Ftest 28.4199 
r
2
 se 0.1548 
q
2
 se 0.1849 
Predicted r
2
 0.7711 
Predicted r
2
 se 0.1856 
External val r
2
 0.9185 
Ext val r
2
 se 0.1397 
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Figure 17. Predicted BCRP activity vs. experimental activity for the training and test sets 
for model 89. 
 
 
There were seven 2D contributing descriptors for Model 89. The seven descriptors used 
in Model 89 are the vdWSurfaceArea, SKMostHydrophobicHydrophilicDistance, 
SAMostHydrophobicHydrophilicDistance, YcompDipole, SddssS(sulfate)E-index, 
DipoleMoment, and SsNH2E-index. These molecular descriptors characterize the 
specific information about the sulfonylureas that drive the interaction with BCRP.  The 
full description of the 2D descriptors of Model 89 are presented in Table 6.  
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Table 6. Molecular Descriptors used in BCRP 2D QSAR Study 
Model Molecular 
Descriptor 
Description 
   
89 vdWSurfaceArea This descriptor signifies total van der Waals surface 
area of the molecule 
 SKMostHydrophobi
cHydrophilicDistan
ce 
SKMostHydrophobicHydrophilicDistance signifies 
the most hydrophobic value on the van der Waals 
surface (by Kellog Method using Slogp) 
 SAMostHydrophobi
cHydrophilicDistan
ce 
SAMostHydrophobicHydrophillicDistance signifies 
the distance between the most hydrophobic and 
hydrophilic point on the vdW surface 
 YcompDipole YcompDipole signifies the y component of the dipole 
moment (external coordinates) 
SddssS(sulfate)E-
index 
SdssS(sulfate)E-index signifies the electropological 
state indices for the number of sulfate groups 
connected with two single and two double bonds 
 DipoleMoment DipoleMoment signifies the dipole moment 
calculated from the partial charges of the molecule 
 SsNH2E-index SsNH2E-index signifies the electropological state 
indices for the number of -NH2 groups connected 
with two single bonds 
  
 
Another way to assess the 2D molecular descriptors in Model 89 is to understand the 
weight % contributions of each descriptor. As shown in Figure 18, four of the molecular 
descriptors had positive contributions on the model: vdWSurfaceArea, 
SAMostHydrophobicHydrophilicDistance, YcompDipole, and SsNH2E-index 
contributing approximately 70% to the model overall. Three molecular descriptors had 
negative contributions on the model: SKMostHydrophobicHydrophilicDistance, 
SddssS(sulfate)E-index, and DipoleMoment contributing the remaining 30% to the 
model. The % contribution values of each molecular descriptor are presented in Figure 
18. 
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            Figure 18. Graph depicting 2D QSAR variables and % contributions. 
 
 
The 2D equation defining the BCRP and sulfonylurea activity is presented here: 
pBCRPEfflux = vdWSurfaceArea 0.0038(±0.0003) 
SKMostHydrophobicHydrophilicDistance -0.0315(±0.0072) 
SAMostHydrophobicHydrophilicDistance 0.0316(±0.0089) YcompDipole 
0.0531(±0.0134) SddssS(sulfate)E-index -0.0600(±0.0175) DipoleMoment -
0.0562(±0.0237) SsNH2E-index 0.0445(±0.0207) -1.6761 
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Molecule 
Efflux 
Ratio 
logEfflux 
Ratio 
Predicted 
logEfflux 
Ratio  
Residual Molecule 
Efflux 
Ratio 
logEfflux 
Ratio 
Predicted 
logEfflux 
Ratio  
Residual 
1 2.78 0.444 0.519 -0.075 29 3.34 0.524 0.681 -0.157 
2 1.9 0.279 0.225 0.054 30 1.49 0.173 0.473 -0.299 
3 3.21 0.507 0.32 0.187 31 3.37 0.528 0.337 0.191 
4 3.45 0.538 0.437 0.101 32 4.28 0.631 0.404 0.227 
5 1.14 0.057 0.081 -0.024 32 4.28 0.631 0.404 0.227 
6 1.01 0.004 -0.138 0.143 33 3.32 0.521 0.528 -0.007 
7 0.88 -0.056 -0.343 0.288 34 7.67 0.885 0.765 0.119 
8 0.87 -0.06 0.057 -0.118 35 3.9 0.591 0.497 0.094 
9 0.67 -0.174 -0.219 0.045 36 1.87 0.272 0.242 0.03 
10 0.54 -0.268 -0.133 -0.134 37 2.75 0.439 0.539 -0.1 
11 0.55 -0.26 -0.254 -0.006 38 0.877 -0.057 0.231 -0.288 
12 0.59 -0.229 -0.148 -0.081 39 1.76 0.246 0.223 0.023 
13 0.72 -0.143 -0.273 0.13 40 0.881 -0.055 0.306 -0.361 
14 0.91 -0.041 -0.018 -0.023 41 13.1 1.117 1.06 0.057 
15 0.44 -0.357 -0.371 0.014 42 3.7 0.568 0.686 -0.118 
16 0.5 -0.301 -0.474 0.173 43 8.33 0.921 0.829 0.091 
17 2.32 0.365 0.545 -0.179 44 1.3 0.114 0.284 -0.17 
8 3.72 0.571 0.721 -0.151 45 13.4 1.127 1.237 -0.11 
19 2.41 0.382 0.358 0.024 46 6 0.778 0.747 0.031 
20 1.76 0.246 0.277 -0.031 47 4.54 0.657 0.679 -0.022 
22 2.4 0.38 0.194 0.186 48 7.45 0.872 0.808 0.064 
23 6.54 0.816 0.583 0.233 49 12.4 1.093 1.102 -0.008 
24 1.65 0.217 0.14 0.077 50 2.3 0.362 0.561 -0.199 
25 4.18 0.621 0.497 0.124 51 3.13 0.496 0.474 0.022 
26 3.67 0.565 0.455 0.11 52 0.73 -0.137 0.114 -0.25 
27 2.72 0.435 0.575 -0.14 53 4.11 0.614 0.664 -0.05 
28 5.43 0.735 0.548 0.187 54 3.88 0.589 0.599 -0.01 
  
Table 7. Molecules used in the BCRP study with experimental, predicted and residual 
activity values. 
 
The sulfonylurea interactions with Pgp and BCRP were well characterized in the 
respective 2D QSAR models. Both 2D QSAR models were comprised 7 and 8 molecular 
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descriptors defining the activity in BCRP and Pgp, respectively. Most of the descriptors 
defining the activity for either Pgp of BCRP were unique, however there were 3 
descriptors that were shared in the 2D models. The max hydrophibic-hydrophillic 
distance (positive coefficient for both), the sulfate index (negative coefficient for BCRP, 
positive for Pgp) and the dipole moment (negative coefficient for BCRP and positive for 
Pgp) were shared in both models and are therefore important features to describe the 
sulfonylurea interactions with the ABC transporter proteins in general. Examining the 
values individual values for each descriptor demonstrate the impact on each model and 
help us understand the importance of each on the respective models. It is difficult to 
compare the importance of the descriptors in each model directly due to the nature of the 
statistical analysis (kNN vs MLR), however the similarity in the structure and function of 
the molecules cannot be overlooked when dealing with the ABC transporters. The shared 
descriptors and the definitions are presented in Table 8.  
 
Table 8. Descriptors shared by both Pgp and BCRP 2D QSAR Models 
Molecular 
Descriptor 
Description 
SAMostHydrophobi
cHydrophilicDistan
ce 
SAMostHydrophobicHydrophillicDistance signifies the 
distance between the most hydrophobic and hydrophilic 
point on the vdW surface 
SddssS(sulfate)E-
index 
SdssS(sulfate)E-index signifies the electropological state 
indices for the number of sulfate groups connected with two 
single and two double bonds 
DipoleMoment DipoleMoment signifies the dipole moment calculated from 
the partial charges of the molecule 
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Pgp 3D QSAR DISCUSSION 
The optimum model to describe the sulfonylurea-Pgp interaction with the 3D space was 
obtained in Model 10, using the MLR methodology, also using the sphere exclusion 
technique, and with the added Del Re energy minimization calculations for the 3-
dimensional space. 
159
 Del Re energy minimizations are based on the dissociation 
energies of the bonds, accounting for the overlap of the dipole moments and often used in 
QSAR modeling parameterization. 
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 Model 10 parameters are presented in Table 4 and 
proved very robust and demonstrated excellent linearity with an r
2
 value of 0.8304, a 
cross validation value of 0.7501, and a predicted r
2
 value of 0.7349, also not 
overpredicting against the external validation r
2
 of 0.8806. The external predictability of 
Model 11 was determined by the predicted r
2
 (pred_r 
2
) value, which was 0.8806, 
meaning that the model has a prediction rate of 88.06%. The 3D model was better than 
the 2D QSAR model in the cross validation (q
2
 of 0.7501 vs 0.7151) and external 
validation r
2
 (0.8806 vs 0.8266); however, the predicted r
2
 capability was better in the 2D 
model (0.8150 vs 0.7349).    
 
The 3D QSAR model statistical parameters and values are presented in table 9. 
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Table 9. The Pgp 3D QSAR Model Statistical Parameters and Values. 
 
Statistical 
Parameter 
3D QSAR MLR 
Model 10 
n 58 
deg. of freedom 44 
r
2 
0.8304 
q
2 
0.7501 
Ftest 19.5892 
r
2
 se 0.2128 
q
2
 se 0.2584 
Predicted r
2
 0.7349 
Predicted r
2
 se 0.6234 
External val r
2
 0.8806 
Ext val r
2
 se 0.1683 
 
Plotting the predicted Pgp activity against the experimental activity also provides an 
assessment of the model. As shown in Figure 19, the predicted vs experimental Pgp 
activity for the training and test sets showed excellent linearity. There was one outlier in 
the test set (molecule 77) that had a very high Papp value (12.4) but was predicted to be 
low due to the 2-methyltetrahydrofuran ligand attached to the benzamido group. 
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Figure 19. Graphical representation of predicted Pgp activity vs. actual activity for the 
training and test sets for MLR Model 10. 
 
There were eleven 3D descriptors for Model 10 representing the steric and electrostatic 
space contributing to the activity model, as presented in Figure 19. The descriptors are 
denoted as electrostatic (E) or steric (S), and the corresponding number is the location of 
the grid surrounding the molecule.  The steric descriptors represented the largest positive 
contributors to the QSAR model with S_1446, S_1970, S_3790, S_2316, S_1715, S_834, 
S_2320, and S_3219 positively contributing to the model, and accounting for 
approximately 75% of the weighted activity overall. One steric descriptor (S_1060) and 
the two remaining electrostatic descriptors (E_3205 and E_714) negatively contributed to 
the interaction.  
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Figure 20. Steric and Electrostatic descriptors contributions for the 3D QSAR modeling 
of Pgp activity for 3D QSAR del re energy minimization.  
 
                                      
Figure 21. Glyburide molecule showing the points of Pgp 3D model.  
 
The plots in Figure 21, show the steric and electrostatic field points indicating the region 
of local fields round the aligned molecule Glyburide.  The colored spheres (blue and 
green) represent the fields, steric and electrostatic, respectively. In the 3D QAR model, 
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the steric descriptors with positive values represent areas with high steric tolerances, 
meaning bulky groups would be favored; and steric descriptors with negative values 
indicate areas with low tolerance, meaning smaller groups would be favored. The 
electrostatic descriptors with positive values represent areas where electron-donating 
groups are favored; and the negative values represent areas where the electron-
withdrawing groups are favored. 
 
The equation governing the sulfonylurea-Pgp 3D QSAR model is: 
pPgp Effluxgas mars = - 0.0152(±0.0024) (S_1060) + 0.0236(±0.0030) (S_1446) + 
0.0163(±0.0026) (S_1970) + 0.0134(±0.0058) (S_3790) + 0.0167(±0.0032) (S_2316) + 
0.0170(±0.0036) (S_1715) + 0.0149(±0.0032) (S_834)  + 0.0085(±0.0028) (S_2320) + 
0.0177(±0.0039) (S_3219) -0.0357(±0.0126) (E_3205) -0.0493(±0.0176) (E_714) + 
0.2696 
 
 
The equation above shows the contributions for the various descriptors contributing to the 
explanation of the Pgp activity. Those descriptors having a positive value shows that an 
increase is needed for Pgp activity. Conversely, there were three descriptors that show an 
inversely proportional relationship in that decreasing the value of that descriptor will 
increase the Pgp activity. From the model it is observed that the electrostatic fields E_714 
and E_3205 have negative coefficients on both the cyclohexyl moiety and on the 
carbonyl of the amide, respectively. Also, the negative coefficient on steric descriptor 
S_1060 shows that the cyclohexyl ring needs smaller group at that position to increase 
the Pgp activity. The remaining steric field descriptors have positive coefficients, and 
therefore would require bulkier groups to increase the Pgp activity. The S_1446, S_1715, 
S_1970, S_2316, S_2320, S_3129, and S_3790 steric descriptors show an increase in Pgp 
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activity with the increased bulky groups at the cyclohexyl ring, urea, sulfonyl, central aryl 
ring, benzamido, and the halogen substitution of the benzamido group, respectively. 
 
Molecule 
Efflux 
Ratio 
logER 
Ratio 
Pred 
Residual Molecule 
Efflux 
Ratio 
logER 
Ratio 
Pred 
Residual 
logER  logER  
1 6.39 0.806 0.635 0.17 41 1.76 0.246 0.226 0.019 
2 2.75 0.439 0.246 0.194 42 2.24 0.35 0.197 0.153 
3 6.21 0.793 0.384 0.409 43 1.52 0.182 0.209 -0.027 
4 5.51 0.741 0.557 0.184 44 1.09 0.037 -0.012 0.05 
5 2.3 0.362 0.394 -0.033 45 1.34 0.127 0.125 0.002 
6 0.93 -0.032 0.16 -0.191 46 1.54 0.188 0.146 0.041 
7 0.9 -0.046 0.151 -0.197 47 3.57 0.553 0.661 -0.108 
8 0.99 -0.004 0.288 -0.292 48 12.4 1.093 1.31 -0.217 
9 0.53 -0.276 -0.141 -0.135 49 3.05 0.484 0.922 -0.438 
10 0.82 -0.086 0.354 -0.441 50 5.89 0.77 0.177 0.593 
11 0.76 -0.119 -0.236 0.117 51 2.89 0.461 0.286 0.175 
12 0.7 -0.155 0.38 -0.535 52 4.37 0.64 0.754 -0.113 
13 0.65 -0.187 0.267 -0.454 53 12.5 1.097 0.99 0.107 
14 0.74 -0.131 0.175 -0.306 54 9.38 0.972 1.16 -0.188 
15 0.55 -0.26 -0.264 0.004 55 1.36 0.134 0.015 0.118 
16 0.56 -0.252 -0.277 0.025 56 57.4 1.759 0.616 1.143 
17 5.4 0.732 0.717 0.016 57 5.35 0.728 0.187 0.541 
18 10.2 1.009 0.924 0.085 58 7.64 0.883 0.851 0.032 
19 4.17 0.62 0.746 -0.126 59 6.7 0.826 0.687 0.139 
20 2.99 0.476 0.122 0.354 60 16.5 1.217 1.433 -0.216 
22 9.3 0.968 0.793 0.176 61 3.62 0.559 0.735 -0.176 
23 2.43 0.386 0.467 -0.081 62 3.08 0.489 0.466 0.022 
24 1.33 0.124 0.068 0.056 63 9.74 0.989 1.062 -0.073 
25 9.73 0.988 0.606 0.382 64 7.81 0.893 0.753 0.139 
26 8.45 0.927 0.727 0.2 65 14.3 1.155 1.162 -0.007 
27 3.83 0.583 0.452 0.132 66 11.7 1.068 0.934 0.134 
28 12.8 1.107 1.107 0 67 1.72 0.236 0.24 -0.004 
29 5.41 0.733 0.632 0.101 68 28.4 1.453 1.309 0.145 
30 2.04 0.31 0.259 0.05 69 25.5 1.407 1.477 -0.07 
31 8.52 0.93 0.02 0.91 70 7.45 0.872 0.991 -0.119 
32 12.9 1.111 1.034 0.077 71 18.1 1.258 0.828 0.43 
33 21 1.322 0.633 0.69 72 24.3 1.386 1.375 0.01 
34 15.3 1.185 1.271 -0.086 73 1.34 0.127 0.077 0.051 
35 3.37 0.528 0.562 -0.035 74 1.06 0.025 -0.104 0.13 
36 1.56 0.193 0.096 0.097 75 2.93 0.467 0.574 -0.107 
37 5.08 0.706 0.825 -0.119 76 4.29 0.632 0.517 0.115 
38 0.44 -0.354 0.147 -0.5 77 0.85 -0.072 0.945 -1.017 
39 1.62 0.21 0.122 0.088 78 12.4 1.093 0.908 0.185 
40 0.68 -0.166 0.224 -0.39 79 6.07 0.783 0.661 0.123 
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Table 10. Molecules used in the Pgp study with experimental, predicted and residual 
activity values. 
 
     BCRP 3D QSAR DISCUSSION 
The optimum model to describe the sulfonylurea-BCRP interaction with the 3D space 
was obtained in Model 65, using the MLR methodology, also using the sphere exclusion 
technique, and with Gasteiger Marsili energy minimization calculations.  
161
  Gasteiger 
Marsili energy calculation for the 3D space is a method of calculating the energies of the 
atomic charges in the sigma and pi systems and is also used routinely as an energy 
calculation tool for QSAR modeling.
162
 Model 65 also proved very robust and 
demonstrated excellent linearity with an r
2
 value of 0.9063%, a cross validation value of 
0.7789 and a predicted r
2
 value of 0.8687.  The predictive ability of all the 3D QSAR 
models was further confirmed by the predicted r
2
 and the external validation test data set, 
both of which demonstrated excellent acceptance criteria with only a slight 
overprediction when comparing the predicted r
2
 to the external validation r
2
 values.   
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The BCRP 3D QSAR model statistical parameters and values are presented in table 11. 
Statistical 
Parameter 
3D QSAR MLR 
Model 65 
n 58 
deg. of freedom 32 
r
2 
0.9063 
q
2 
0.7789 
Ftest 38.7034 
r
2
 se 0.1290 
q
2
 se 0.1981 
Predicted r
2
 0.8687 
Predicted r
2
 se 0.2092 
External val r
2
 0.8121 
Ext val r
2
 se 0.3436 
 
Plotting the predicted BCRP activity against the actual experimental activity also 
provides an assessment of the model. As shown in Figure 22 the predicted vs actual 
BCRP activity for the training and test sets showed excellent linearity. 
 
Figure 22. Graphical representation of predicted BCRP activity vs. actual activity for the 
training and test sets for MLR Model 65. 
 
There were eight 3D contributing descriptors for Model 65 representing the steric and 
electrostatic space surrounding the molecules. For reference, the descriptors are denoted 
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as electrostatic (E) or steric (S), and the corresponding number is the location of the grid 
surrounding the molecules.  The steric descriptors were the largest positive contributors 
to the QSAR model with the S_1940, S_1950, and S_1292 descriptors contributing 
approximately 58% to the overall model. The steric descriptor S_1926 and S_2156, and 
the electrostatic descriptors E_1375, E_1458, and E_2086 contributed negatively to the 
interactions. contribution plot in Figure 23 accounts for the individual descriptors 
contributions toward the biological activity. 
 
Figure 23. Steric and Electrostatic descriptors contribution plots for the 3D QSAR 
modeling of BCRP activity for 3D QSAR Model 65 Gasteiger-Marsili energy 
minimization. 
 
The equation governing the 3D QSAR model is: 
pBCRP Efflux = 0.0205(±0.0015) (S_1940) + 0.0164(±0.0018) (S_1950) + 
0.0209(±0.0023) (S_1292) - 0.0652(±0.0107) (E_1375) - 0.0134(±0.0027) (S_1926) - 
0.0203(±0.0048) (S_2156) + 0.0149(±0.0032) (S_834)  - 0.0134(±0.0027) (S_2156) - 
0.0203(±0.0048) (E_1458) -0.0225(±0.0041) (E_1458) -0.0370(±0.0099) (E_2086) – 
0.0011 
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The equation above shows the contributions for the various descriptors contributing to the 
explanation of the BCRP activity. Those descriptors having a positive value shows that 
an increase in that descriptor increases the BCRP activity. Conversely, there were three 
descriptors that shown an inversely proportional relationship in that decreasing the value 
of that descriptor will increase the BCRP activity. From the model it is observed that the 
electrostatic fields E_714 and E_3205 need more negative ligands to increase activity, 
with a negative coefficient on both the cyclohexyl moiety and on the carbonyl of the 
amide, respectively. Also, the steric descriptor S_1060 shows that the cyclohexyl ring 
needs smaller group at that position. The field points model is shown in Figure 24. 
 
                                
Figure 24. Field point model detailing steric and electrostatic descriptors for the 3D 
QSAR Modeling. 
 
The plot of steric and electrostatic field points indicates the region of local fields around 
the aligned molecules. 
163
 The colored spheres (blue and green) represent the fields, steric 
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and electrostatic, respectively. In the 3D QAR model, the steric descriptors with positive 
values represent areas with high steric tolerances, meaning bulky groups would be 
favored; and steric descriptors with negative values indicate areas with low tolerances, 
meaning smaller groups would be favored. The electrostatic descriptors with positive 
values represent areas where electron-donating groups are favored; and the negative 
values represent areas where the electron-withdrawing groups are favored.  
From the model it is observed that the steric fields S_1940, S_1950, and S_1292 have 
positive coefficients, meaning that an increase in bulky groups on the benzamido and 
sulfonylurea ligands, respectively, will increase the BCRP activity. Similarly, the steric 
and electrostatic descriptors with negative coefficients require smaller or more negative 
ligands to increase activity. The steric descriptors S_1926 and S_2156 negative 
coefficients mean that smaller ligands at the far side of the substituted benzyl ring will 
increase activity. The electrostatic descriptors E_1375, E_2086 and E_1458 have 
negative coefficients that dictate more negative ligands need to be present on the 
benzamido and central ring to increase activity.  
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Molecule 
Efflux 
Ratio 
logEfflux 
Ratio 
Predicted 
logEfflux 
Ratio  
Residual Molecule 
Efflux 
Ratio 
logEfflux 
Ratio 
Predicted 
logEfflux 
Ratio  
Residual 
1 2.78 0.444 0.201 0.243 29 3.34 0.524 0.596 -0.073 
2 1.9 0.279 0.2 0.079 30 1.49 0.173 0.623 -0.45 
3 3.21 0.507 0.734 -0.228 31 3.37 0.528 0.653 -0.126 
4 3.45 0.538 0.385 0.153 32 4.28 0.631 0.573 0.058 
5 1.14 0.057 0.057 0 32 4.28 0.631 0.831 -0.199 
6 1.01 0.004 0.212 -0.207 33 3.32 0.521 0.669 -0.148 
7 0.88 -0.056 0.106 -0.161 34 7.67 0.885 0.766 0.119 
8 0.87 -0.06 -0.025 -0.035 35 3.9 0.591 0.573 0.018 
9 0.67 -0.174 -0.19 0.016 36 1.87 0.272 -0.037 0.309 
10 0.54 -0.268 0.008 -0.276 37 2.75 0.439 0.493 -0.054 
11 0.55 -0.26 -0.268 0.008 38 0.877 -0.057 0.055 -0.112 
12 0.59 -0.229 0.05 -0.279 39 1.76 0.246 0.239 0.007 
13 0.72 -0.143 -0.263 0.12 40 0.881 -0.055 0.073 -0.128 
14 0.91 -0.041 -0.275 0.235 41 13.1 1.117 0.84 0.277 
15 0.44 -0.357 -0.049 -0.308 42 3.7 0.568 0.38 0.189 
16 0.5 -0.301 -0.171 -0.13 43 8.33 0.921 0.766 0.154 
17 2.32 0.365 0.505 -0.14 44 1.3 0.114 0.05 0.064 
18 3.72 0.571 0.624 -0.054 45 13.4 1.127 1.179 -0.052 
19 2.41 0.382 0.258 0.124 46 6 0.778 0.621 0.157 
20 1.76 0.246 0.661 -0.415 47 4.54 0.657 0.747 -0.089 
22 2.4 0.38 0.73 -0.35 48 7.45 0.872 0.631 0.241 
23 6.54 0.816 1.083 -0.267 49 12.4 1.093 1.178 -0.085 
24 1.65 0.217 0.444 -0.227 50 2.3 0.362 0.583 -0.222 
25 4.18 0.621 0.654 -0.032 51 3.13 0.496 0.628 -0.132 
26 3.67 0.565 0.631 -0.067 52 0.73 -0.137 -0.234 0.098 
27 2.72 0.435 0.37 0.065 53 4.11 0.614 0.614 0 
28 5.43 0.735 0.665 0.069 54 3.88 0.589 0.55 0.039 
  
 
Table 12. Molecules used in the BCRP study with experimental, predicted and residual 
activity values. 
 
PHARMACOPHORE MODELING DISCUSSION 
A pharmacophore model is a 3D representation of the steric and electrostatic features 
needed to ensure the optimal molecular interactions with the desired biological activity. 
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Pharmacophore identification studies were performed using the MolSign module of 
the VLifeMDS® v4.6 software package. In general, the pharmacophore models consist of 
Hydrogen bond donors, Hydrogen bond acceptors, aromatic/hydrophobic groups, and 
positive of negative ionizable groups. The features of the pharmacophore are color coded 
as Hydrogen bond donors (Green), Hydrogen bond acceptors (Blue), hydrophobic 
(Orange), Aliphatic (Buff), Negative (Dark Red), and Positive (Dark Green). For visual 
reference, the software designates the smaller colored spheres to represent the key 
features of Glyburide, with the larger spheres representing the more common key features 
across the series of sulfonylurea analogs (larger spheres are shown in Pharmacophore 
models). In the case of Glyburide, there were 12 key pharmacophore points identified in 
the molecule, as shown in Figure 25. 
 
                                 
                                    Figure 25. Glyburide Pharmacophore features. 
 
Like the QSAR modeling efforts, the first and second-generation sulfonylureas were 
analyzed against the low energy conformer Glyburide as the template. As expected, only 
5 of the sulfonylureas overlaid precisely to the core conformer structure. The first-
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generation sulfonylureas are lacking the benzamido ligand of the scaffold and therefore 
only partially fit the conformer; with Glimepiride, Glisoxepide, Gliquidone, Glipizide, 
and Gliclazide, all fit the scaffold overlay. 
For the pharmacophore evaluation, the 45 sulfonylurea analogs demonstrating Pgp 
activity, and the 25 sulfonylureas demonstrating BCRP activity were used to build the 
respective models. In the VLifeMDS® MolSign software module, Glyburide was loaded 
as the reference molecule. There are three parameters to optimize that influence the 
pharmacophore generation: primary feature count, tolerance limit and maximum distance 
allowed.  Briefly, the primary feature count is the number of features in the 
pharmacophore; the tolerance limit is set to between 10-30% and accounts for variability 
in the pharmacophore features; and the max distance allowed determines how far apart a 
feature can be from another (max distance is 15Å). For the pharmacophore generation, 
the parameters where optimized to capture the best feature coverage of the molecules in 
the study. For both the reported Glyburide pharmacophores, the feature count was set to 
5, the tolerance limit was set to 10%, and the max distance was set to 10Å. 
These parameters were optimized to maximize the pharmacophore model activity to 
capture as many molecular features as possible without dampening the sensitivity. Too 
few or too many features will not allow for a robust model by including too many or too 
few molecules in the model. Meaning, allowing for too wide criteria on the tolerance may 
include features that are not shared across the entire molecule set; on the feature count, 
limiting the feature count to a reasonable value (i.e., 5) forces the algorithm to pick the 
best features to define the activity without selecting the entire molecule; and limiting the 
distance allows for feature resolution across the entire molecule.  The impact of these 
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assumptions is that we are building a local model maximizing the activity of the 
sulfonylureas against Glyburide, to best explain the transport behavior of Glyburide in 
the ABC transporters Pgp and BCRP. 
From the pharmacophore generation, the sulfonylurea-Pgp and sulfonylurea-BCRP 
pharmacophores each contained 5 key features describing the steric and electrostatics of 
the protein-sulfonylurea activity. The key pharmacophore features were aromatic rings, 
hydrogen donors, and hydrogen acceptors. Though these features were similar across 
both ABC transporter models, there were important differences concerning the activities 
and therefore the pharmacophore models will be discussed separately. 
 
SULFONYLUREA-Pgp PHARMACOPHORE 
The sulfonylurea-Pgp pharmacophore contained 5 features, 2 aromatic rings, 1 Hydrogen 
donor, and 2 Hydrogen acceptors, as pictured in Figure 26. The H donor feature was 
assigned to the amide of the sulfonylurea, with the H acceptors being the carbonyl of the 
sulfonylurea and benzamido moieties. The benzamido and aryl ring accounted for the two 
aromatic rings. The 5-point pharmacophore was supported by 39 of the 45 molecules, 
sharing all five of the key features. This was the maximum number of sulfonylurea 
analogs included with the 5-feature pharmacophore. The inclusion rate was higher with 
less features of the pharmacophore, but the pharmacophore was not as strong at 
explaining the features responsible for the activity. This is an important step in 
pharmacophore generation, the pharmacophore model should represent the activity of the 
molecules studied as closely as possible. 
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                    Figure 26. Glyburide Pharmacophore detailing the 5 points of interest.  
As expected, the 5 second generation sulfonylureas fit the pharmacophore template well, 
being similar in size and structure to Glyburide. The first-generation sulfonylureas 
however are much smaller in size and do not contain the ligands attached at the para 
position of the arylsulfonylurea core structure. For reference, the core sulfonylurea 
structure is presented in Figure 26, with the para position of the arylsulfonylurea ring 
denoted as R1 circled in blue. 
 
 
Figure 26. Sulfonylurea-BCRP Pharmacophore denoting the para position of the 
arylsulfonylurea ring. 
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SUFONYLUREA-BCRP PHARMACOPHORE 
Similar to the Pgp pharmacophore, the sulfonylurea-BCRP pharmacophore contained 5 
features, but differed in the types and location of the features. The 2 aromatic rings, 1 
Hydrogen donor, 1 Hydrogen acceptors, and 1 hydrophobic as pictured in Figure 27. The 
H donor feature was assigned to the amide of the sulfonylurea, with the H acceptor 
assigned to the carbonyl of the benzamido moiety. As expected, the benzamido and aryl 
rings accounted for the two aromatic rings. The hydrophobic feature was assigned to the 
substituted benzamido ring, near the Chlorine. The 5-point BCRP pharmacophore was 
supported by 21 of the 25, sharing all five of the key features to represent the broadest 
group of the molecule set. Again, this was the highest number of sulfonylureas included 
in the 5-point pharmacophore. The inclusion rate was higher for lower feature count 
pharmacophores but did not represent all of the key features properly. The 
pharmacophore model is presented in Figure 28. 
 
       
    Figure 28. Glyburide-BCRP Pharmacophore detailing the 5 points of interest.  
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PHARMACOPHORE MODELING DISCUSSION 
The value of the pharmacophore model is the highlight of the ligands at certain points on 
the molecule structure that drive the structure activity relationship. This is possible to 
accomplish as all of the molecules in the study have been normalized to the most active 
molecule (Glyburide), providing the means to identify the structural changes that are 
believed to be implicated in the observed pharmacological activity.  
The two pharmacophore models generated showed many similarities and some 
interesting differences. Both models shared the two aromatic rings, but differed in the 
hydrogen donor, hydrogen acceptor and hydrophobic features. For the Pgp 
pharmacophore, the H donor feature represented the amide of the sulfonylurea, with the 
H acceptors being the carbonyls of the sulfonylurea and benzamido moieties. The Pgp 
pharmacophore represented a uniform feature distribution across the molecule driving the 
activity. The BCRP pharmacophore however, highlighted the importance of the 
substituted benzamido ligand for BCRP activity, with the H donor feature representing 
the amide of the sulfonylurea, the H acceptor representing the carbonyl of the benzamido 
moiety, and the hydrophobic feature was assigned to the substituted benzamido ring, near 
the Chlorine. This hydrophobic character is the main difference between the Pgp and 
BCRP activity models. 
This combination of hydrophilic and hydrophobic character matches well with the 
understanding that these ABC proteins rely on these broad moieties instead of very 
specific chemical structures. 
165
 Clearly from both models, the activity in both the Pgp 
and BCRP models was driven by the arylsulfonylurea and the substituted benzamido 
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ring. The non-substrates of both proteins were lacking at least the benzamido ligand and 
the steric and electrostatic character that it brings. 
As expected, a large set of the sulfonylurea analogs that do not have Pgp or BCRP 
activity, also contain some or all of these features. However, for those molecules that do 
not have all the key feature points for either pharmacophore, the activity is obviously 
lacking. For those molecules that share the key features, but still lack activity, there were 
a few noticeable differences. These molecules also had other substituents that interfered 
with the activity, bulky groups, or electron withdrawing/adding.  
As there is no crystal structure of Pgp or BCRP currently available, the pharmacophore 
model allows for a mapping of the key features on the molecule that relate to an increase 
in activity. The specificity of the pharmacophore model will be lacking as a true binding 
pocket definition of size and electrostatics for either protein is not known. However, the 
pharmacophore models for both Pgp and BCRP represent the key molecular features 
(steric/electrostatic character) of the ligands on the molecule Glyburide that explain the 
ABC transporter activity. 
 
GENERAL DISCUSSION 
The oral hypoglycemic sulfonylurea molecule Glyburide has been shown to be actively 
transported from various biological tissues though a pronounced interaction with the ATP 
binding cassette (ABC) active transporter proteins.  In our research, the interactions of a 
series of sulfonylureas and two of the ABC transporter proteins (Pgp and BCRP) were 
studied in two MDCK cell monolayer transport assays, MDCK-MDR and MDCK-BCRP. 
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The cell lines are rigorously characterized and shown to have no other transporter 
proteins present, so the transport activity is regarded as a direct effect of the molecule and 
the specific protein. 
In total, 78 sulfonylurea analogs were used in the Pgp assays, and 54 were used in the 
BCRP assay. A subset of these sulfonylurea analogs exhibited either Pgp or BCRP 
activity with 45 demonstrating Pgp substrate activity, and 25 demonstrating BCRP 
activity. Substrate activity was determined based on the Efflux Ratios (ER), which is the 
ratio of the transport in the basolateral to apical direction divided by the transport in the 
apical to basolateral direction. The integrity of the cell monolayers was check by trans-
epithelial resistance measurements, and the ER benchmarked with positive and negative 
controls, showing the cell monolayers are performing as expected. The negative control 
for both assays was antipyrine, which demonstrated equivalent transport in both 
directions; and compounds were chosen for the positive controls that are known 
substrates for each protein. Specifically, the positive controls were topotecan for the 
MDCK-BCRP cells, and vinblastine for the MDCK-MDR cells. The molecules whose 
ER in the Pgp an BCRP transport assays were ≥ 2.5 (2.5 times greater transport in one 
direction) were considered substrates. The second-generation sulfonylureas and analogs 
demonstrated considerable Pgp and BCRP activity, further confirming the ability of the 
sulfonylurea analogs to be substrates of both ABC transporter proteins.  
Care was taken to select the experimental concentrations that resulted in relevant and 
comparable results between the two studies. Of special note are the three sulfonylureas 
Glimepiride, Glisoxepide and Gliquidone, that were identified as substrates of Pgp and 
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BCRP and have not been previously reported.  Our results also confirm Glyburide as a 
substrate of Pgp and BCRP, as previously reported. 
166
  
The first reported carrier mediated transport of Glyburide was carried out by Goldstein et 
al demonstrating that Glyburide was a substrate of Pgp.
167
 As discussed earlier, 
subsequent studies have repeatedly demonstrated that Glyburide is actively transported 
by other ABC transporters, mainly BCRP and MRPs. As there are many studies with 
BCRP and Glyburide, we chose to revisit the earlier Pgp transport of Glyburide, to 
understand the substrate potential of the sulfonylurea class. The first part of our research 
was to test the concentration dependence transport activity of Pgp using the MDCK-
MDR cell line. Glyburide, Glipizide, Glimepiride, Gliquidone, and Glisoxepide were run 
in the transport assay, with concentrations varying from 2-100µM, and the apparent 
permeability and subsequent ER were calculated at each concentration. 
 The four sulfonylureas showed carrier mediated transport activity as the rates of efflux 
from the Pgp assay exceeded the rates of absorption for each Glyburide, Glimepiride, 
Gliquidone, and Glisoxepide. These four analogs showed linear response in uptake and 
efflux until the highest concentrations. At such high concentrations, the sulfonylureas 
were acting as inhibitors and blocking their own up transport. This was expected as 
Glyburide, Glipizide and Gliclazide have been reported as a Pgp inhibitor at high 
concentrations. 
168
 Glipizide and Gliclazide, though structurally similar to the second-
generation sulfonylureas, demonstrated no/slight Pgp activity and no BCRP activity in 
our studies, with the rate of transport similar in both directions. It has also been reported 
that both Glipizide and Gliclazide are Pgp substrates at high concentrations (100µM and 
74 
 
500µM, respectively), but at the lower concentrations in our study, neither compound 
was shown to have any Pgp or BCRP activity.
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The second part of our research looked at the transport mediated activity of the series of 
sulfonylurea analogs at a standard concentration of 2µM. The concentration was held 
constant so as to identify the structure activity relationship and build three-dimensional 
pharmacophore and QSAR models to explain the nature and character of the Pgp- and 
BCRP-sulfonylurea interactions. The cell assays were performed for all available 
sulfonylurea analogs, and the apparent permeability and subsequent ER were calculated. 
The ER were then converted to log(ER) to use as the biological activity in the two and 
three-dimensional QSAR models. The 45 compounds that showed Pgp activity and the 25 
compounds that showed BCRP activity were used to build the respective pharmacophore 
and QSAR models detailing the molecular attributes of the interaction.  
The pharmacophore models demonstrated that the two main sections of the molecule, the 
benzamido and aryl-sulfonylurea moieties, are key to explaining the interaction with both 
Pgp and BCRP.  In fact, in our study the molecules that lacked either substituent showed 
no Pgp/BCRP activity. The pharmacophore model for each protein detailed 5 features 
responsible for activity, with the models consisting of aromatics, 2 hydrogen acceptors, 1 
hydrogen donor, and 1 hydrophobic group. The five-feature count was determined to be 
the most appropriate value to use based on trial and error with the software program. 
There was a balance of too few/too many features in the pharmacophore and still have a 
model that represents the key points across the entirety of the molecule. The Pgp 
pharmacophore consisted of two aromatic rings, two hydrogen acceptors and one 
hydrogen donor. Meanwhile, the BCRP pharmacophore shared the aromatic and one 
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hydrogen acceptor but differed in that there was only one hydrogen donator, with the 
added feature of hydrophobic character on the benzamido ligand. The Pgp and BCRP 
pharmacophore models are presented in Figure 29 as simple diagrams.  
 
           
Figure 29. Simple diagrams of key pharmacophore features of the Pgp (left) and BCRP 
(right) models, superimposed on the molecule Glyburide. Key: green aromatic, blue 
hydrogen acceptor, red hydrogen donator, and orange hydrophobic. 
 
Further evaluation of the sulfonylurea activities to the molecular structure through the 3D 
QSAR models detailed the individual molecular features that add or subtract from the 
observed Pgp or BCRP activity. Based on the sulfonylurea analog structures tested in our 
work, the ligands attached at the far end of the aryl-sulfonylurea section of the molecule 
appear to be less influential, as the structures can range from a simple alkane to complex 
with multiple aromatic rings. Meanwhile, the ligands attached to the para position of the 
arylsulfonylurea drive the activity of both Pgp and BCRP. Specifically, the benzamido is 
needed for either activity; with the ligands attached to the ring also influencing the 
activities.  From our work, the ligands that increase the electron cloud are too hydrophilic 
and decrease the activities. Conversely, the ligands that increase hydrophobic character or 
maintain the electronics of the benzyl ring, maintain or increase the activities. A 
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schematic representation of the core arylsulfonylurea attached to the benzamido ligand is 
presented in Figure 30 with some example ligands that increase of decrease activity based 
on our work.  
 
                    
Figure 30. Core structure of sulfonylurea with the potential ligands that can increase or 
decrease the activity for both Pgp and BCRP. Note: light blue highlights benzamido 
ligand; dark blue highlights arylsulfonylurea; blue circle denotes where bonding occurs 
for ligands; and blue semi-circle denotes where bonding occurs for ligands.  
 
The SAR of the sulfonylureas with the SUR1 receptor was first reported by Meyer et al 
in 1999 and described the ligands on Glyburide that are required for SUR1 activity. 
Meyer reported that removing the cyclohexyl or benzamido ligand marketed reduced 
SUR1 activity. In fact, swapping the larger ring structures for smaller, less bulky groups 
(i.e., methyl group) had the same effect. 
170
 This was also witnessed in our work, the 
sulfonylureas that more closely resembled the Glyburide structure, containing the 
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benzamido and aryl-sulfonylurea portions, were more likely to be substrates of Pgp and 
BCRP. Similarly, if the sulfonylurea or analogs were missing one or the other benzamido 
of aryl-sulfonylurea portion, then they were not recognized as Pgp or BCRP substrates. 
Further, as demonstrated in the pharmacophore models, strategic placement of the 
hydrogen donating/accepting, aromatics, hydrophobic, or bulky groups increased the Pgp 
and BCRP activity. 
Knowing that the sulfonylureas work through binding to the SUR1 protein (ABCC8), 
which is also an ABC transporter protein like Pgp and BCRP, we looked to what is 
known of the sulfonylurea and the target protein in the treatment of diabetes. The 
sulfonylureas are designed to act on the SUR1 receptor, and therefore it would not be 
controversial to propose that the same elements responsible for binding to the SUR1 
receptor would also positively affect the interaction with Pgp or BCRP. This is exactly 
what was determined by Bessadock et al. In fact, Bessadock performed a phylogenic 
protein search of the ABC transporter proteins demonstrating that Pgp and SUR1 are 
from the same protein cluster. Similarly, Vila-Carriles et al proposed that the SAR 
driving the 2
nd
 generation sulfonylureas has been to increase the binding affinity with the 
sulfonylurea receptor, interacting with both the proposed A and B sites of the SUR 
receptor, as shown in Figure 31. 
171
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Figure 31. Representative binding sites on SUR1, tolbutamide and glyburide presented as 
examples, reproduced from Vila-Carriles. 
 
The second-generation sulfonylureas were designed to interact with both binding pockets 
of the SUR1 protein, and in doing so were considerably more potent than the preceding 
generation. This increased potency across the generations is the same impact as seen in 
our work, in fact it mimics it very closely. Simply, those analogs that did not have both 
the arylsulfonylurea and benzamido ligands did not exhibit Pgp or BCRP activity. 
Building on the similarity of the SUR1 and Pgp transporter proteins theory, Bessadock et 
al have reported the Glyburide pharmacophore based on the 3-dimensional alignment of 
Glyburide with vinblastine, a known Pgp inhibitor.  Their pharmacophore models called 
out five key features: the two aromatic rings, two hydrogen donor groups (NH and NH 
proximal to S), and one electron donor group (C=O) and is presented in Figure 30. Our 
work is very much in line with these findings and confirms the Bessadock model. Also, 
this model is representative of the hypothesized molecule features of the SUR1, which 
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was expected based on the proximity on the ABC membrane transporter phylogenic tree. 
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Figure 32. Key features in Glyburide-Pgp interaction, reproduced from Bessadock. Key: 
green is aromatic red is hydrogen donating, blue is hydrogen accepting groups. 
 
We have found that pharmacophore model presented in Figure 31 accounts for many of 
the same molecular features as reported in our research. We confirm the necessity of the 
two aromatic rings, the two hydrogen donators, and the hydrogen acceptor. These 
features are confirmed by the Pgp substrate activity of the 45 sulfonylurea molecules 
used to build the pharmacophore. 
 
CONCLUSION 
Pgp and BCRP are the most studied ABC transporter proteins and have been found to be 
largely responsible for the multidrug resistance phenomenon in cancer therapies, but 
characterization of either has been difficult due to the lack of the membrane crystal 
structure and general substrate promiscuity. Numerous groups are working towards 
generating the crystal structure of the ABC transporters, but that work is still years to 
come.
173, 174
 The lack of a defined substrate binding pocket for either Pgp or BCRP 
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proteins has made it difficult to develop one single QSAR or pharmacophore model 
describing the spatial and structural features responsible for activity. 
175
 However, as 
demonstrated here, modeling transporter activity can aid in the understanding and general 
knowledge of the drug-transporter interactions. 
By using a large data set of sulfonylurea analogs representing the space of the oral 
hypoglycemic compounds, we evaluated the substrate activity against to the ABC 
transporter proteins Pgp and BCRP. This resulted in confirming the substrate activity for 
41 analogs in the Pgp assay, and 25 analogs for the BCRP assay. Also, we have 
demonstrated that Glimepiride, Glisoxepide, and Gliquidone are substrates of Pgp and 
BCRP, all of which are previously unreported.  
Our work has also confirmed the pharmacophore model previously presented in 
literature, demonstrating that the sulfonylureas need certain 3-dimensional molecular 
features to be substrates of Pgp and BCRP. Specifically, the benzamido and 
arylsulfonylurea ligands are needed for both Pgp and BCRP activity.  Furthering this 
understanding, is the need for hydrogen donators/acceptors for Pgp activity, and the need 
of hydrogen donators/acceptors and hydrophobic groups for BCRP activity. We also 
found that the substituted benzamido ligand is important for both Pgp and BCRP activity, 
with the ligand attached to the arylsulfonylurea not influencing the activities.  
Computational QSAR models describing the Pgp and BCRP activity for a series of 
sulfonylurea analogs were derived with statistical significance and predictive capabilities 
by using the 2-dimensional and 3-dimensional molecular descriptors presented in the 
VLifeMDS® suite. The predicative ability of these models observed for the training, test, 
and validation sets of molecules make these models useful for designing new compounds 
81 
 
to help explain sulfonylurea-Pgp and sulfonylurea-BCRP activity. Further, this is the first 
set of QSAR studies performed to explain the ABC protein interactions of the 
hypoglycemic sulfonylureas.  
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COMPARISON OF PGP AND BCRP ACTIVITY FOR A SERIES OF 
SULFONYLUREAS BY ACTIVITY CLIFF ANALYIS 
 
ABSTRACT 
Activity Atlas software was used to describe the protein activity between a series of 
sulfonylureas and two of the ATP Binding Cassette (ABC) transporter proteins found 
to be largely responsible for the active transport of Glyburide, Pgp and BCRP. The 
Activity Cliff Analysis has provided a platform to understand the interactions that are 
important to the guide the drug-protein interaction, with the potential to better design 
medications for targeted delivery, for instance in pregnant women. The Activity Cliff 
Analysis is based on the key features of average shape, hydrophobic region, and 
electrostatic patterns of the active compound, and were mined and mapped to detail 
the differences in molecular features driving the ABC protein activity to either Pgp or 
BCRP, specifically.  
As described in our previous work, Activity Atlas was used on a large series of 
sulfonylurea analogs, with the objective of investigating and understanding the 
molecular features that underlie the ABC protein activity in the hopes of better design 
of pregnancy centered medications. As expected there were many similarities in the 
molecular features driving the protein-sulfonylurea activity; but there were also many 
appreciable differences as demonstrated by the analysis of the hydrophobic, 
electrostatic and shape molecular descriptors. When coupled to the 3D QSAR data, the 
Activity Atlas method is particularly useful to visualize and decipher structure activity 
relationships.  
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INTRODUCTION 
Glyburide is a second-generation sulfonylurea used in the treatment of Type II 
Diabetes and has been shown to be especially effective in patients that retain some 
level of insulin production from the pancreatic beta cells. As outlined in the Chapter 1 
Introduction section, researchers began looking to Glyburide as a treatment option for 
gestational diabetes mellitus (GDM). The similarities in the pathophysiology of type II 
and GDM make the oral hypoglycemic agents a smart choice, as compared to insulin. 
In fact, researchers have run numerous clinical studies demonstrating that Glyburide is 
as safe and efficacious in pregnant women as insulin, without many of the insulin 
related difficulties.  
It is in these studies of Glyburide with GDM that researchers have determined a 
unique placental transport activity. Specifically, Glyburide has been demonstrated to 
not cross the placental barrier to any appreciable effect; and, Glyburide will leave the 
fetal compartment against the concentration gradient. 
176,
 
177
 Numerous studies have 
been performed to understand the mechanism responsible, and it has been found that 
Glyburide is actively transported by the ATP binding cassette (ABC) transporter 
proteins, specifically Pgp, BCRP and the MRPs. 
178, 179, 180, 181, 182, 183
    The ABC 
proteins are responsible for the active transport of endogenous and exogenous 
molecules at the barrier membranes throughout the body and have been shown to be 
important players in the pharmacokinetic profiles and disposition of many drugs.  
The documented interactions of Glyburide with the ABC transporter proteins have 
prompted numerous studies evaluating Glyburide, Glipizide, and Gliclazide, with 
similar results. 
184
  In these studies Glyburide, Glipizide, and Gliclazide have been 
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shown to act as substrates or inhibitors of the ATP transporter proteins, depending on 
the concentration dosed. 
185, 186,
 
187
 Figure 32 shows the molecular structure of the 
three sulfonylureas most studied with the ABC transporters. 
 
 
 
 
 
                     Figure 33. Glyburide, Glipizide, and Gliclazide structures. 
 
Many studies have been also performed to understand the placental transport, 
pharmacokinetics/pharmacodynamics, or even to determine the proteins responsible 
for the transport of Glyburide. Our research is the first investigation to study the 
interaction of the sulfonylurea hypoglycemic agents and the ABC transporter proteins. 
In this investigation, a series of sulfonylurea analogs were studied for activity against 
Pgp and BCRP in cell-based transport assays. From the transport assay data, we used 
Cressets Activity Atlas modeling capabilities to identify and describe the key 
molecular features of the sulfonylurea analogs driving the interaction with either the 
Pgp or BCRP. Understanding the differences in the molecular targets could have a 
profound impact on tailored drug delivery and the future of medicine. Specifically, 
these studies may contribute to the design of medications for pregnant women that are 
safe and efficacious, without presenting any harm to the fetus. 
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DATA SET 
A total of 78 sulfonylurea analogs were available to be evaluated in the Pgp and BCRP 
cell-based transport assays. For the Pgp assay, all 78 compounds were tested, with a 
subset of 53 compounds tested in the BCRP assays.  The transport assays were 
performed in Madin-Darby Canine Kidney cells that were transfected with 
overexpressing Pgp or BCRP genes. The transport assays were validated with positive 
and negative transport control compounds, and the cell-monolayers determined 
acceptable for use by measuring the trans-epithelial resistance, as discussed in the 
preceding chapters.  As our research and published articles have shown, Glyburide has 
been reported as a substrate for both Pgp and BCRP, and as a substrate and/or 
inhibitor for other ABC transporters and was therefore used as the reference molecule 
in the studies. As a crystal structure of the sulfonylureas with either protein has not 
been reported, the lowest energy conformation was used in these studies as described 
by Lins et al. 
188
 The lowest energy conformations were determined with by 
Chemaxon® and ChemDraw® software using the MMFF94 energy minimization 
calculation algorithms. 
189, 190
   
The sulfonylurea analogs were tested at a constant concentration (2µM) as per internal 
procedure, with each measurement performed in at least triplicate to assure adequate 
statistical control. The data generated from each cell-based assay was then used to 
build 2D and 3D quantitative structure activity models (QSAR) and a pharmacophore 
model with the molecule design software suite from VLifeMDS. The 2D and 3D 
QSAR models demonstrated excellent predictability, but for the work presented here, 
we will focus on the 3D data set and modeling. For both cell-cased assays, the 3D 
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protein models demonstrated excellent predictability with the Pgp model 
demonstrating a linearity value of r
2
 = 0.8304 and cross-validation of q
2
 =0.7501; and 
the BCRP model demonstrating a linearity value of r
2
 = 0.9083, with a cross-
validation value of q
2
 = 0.7789.  
 
CONFORMATION HUNT AND ALIGNMENT OF MOLECULES 
The first step of the modeling efforts was to generate the most stable conformations 
and to overlay the molecules to a template. As Glyburide is well characterized and 
known to interact with Pgp and BCRP, we used Glyburide as the template molecule 
for conformer hunting and molecular alignments. The conformation hunt was carried 
out with Cresset Forge® software package using the MMFF94 energy minimized 
structure of Glyburide, as we have previously reported. 
191
 The remaining sulfonylurea 
analogs were aligned by the maximum common substructure, using the “very accurate 
but slow” configuration setting to maximize success. The details of the conformation 
hunt parameters are: 
 
Max Number of conformations 1000 
RMS cutoff for duplicate conformers: 0.5 
Gradient cutoff for conformer minimization: 0.1kcal/mol 
Energy window: 3kcal/mol 
 
As with all 3D model generation, the molecular alignment is the most critical first step 
and if not performed correctly can lead to incorrect modeling practices. After 
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completion of the alignment process, visual inspection of the all the molecular 
alignments was performed to make sure there were no disparities between molecules. 
The molecules were evaluated for maximal alignment scores against Glyburide and 
the molecules that were suboptimal, were adjusted and rescored. For example, 
manipulating the phenyl ring of the benzamido substructure proved to be the most 
common fix, and maximized the substructure similarity scores to Glyburide. 
 
ACTIVITY ATLAS MODELING 
The Activity Atlas modeling is part of the Cresset Forge® molecular dynamics 
software package and is routinely used for the design and discovery of new molecules. 
The Activity Atlas modeling suite performs three types of analyses that are key to the 
understanding the activity for the molecules against a specific target, and are defined 
as the Average of the Actives, Activity Cliff Summary, and the Regions Explored 
Analysis. 
192
 For our research, the Regions Explored analysis was not performed as it 
is an assessment of what regions have been explored on the molecule, disregarding the 
biological activity.  For the research performed here, we will discuss the Average of 
Actives and Activity Cliff Analysis, as they will have more insight on the activity of 
the sulfonylureas.  
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ACTIVITY CLIFF MODELING 
As described in the literature references, Activity Analysis modeling can pinpoint the 
critical region of the structure activity relationships (SAR), providing a visual 
summary of the activity cliff for each of the data sets. 
193
 An Activity Cliff is defined 
as a pair or series of structurally similar compounds that have a large difference in 
potency or activity.
194
 This is especially pertinent for sets of molecules run in different 
assays, allowing the data to be combined and compared to further characterize the 
molecules, the associated biological activity and critical differences in SAR. 
As discussed by Cheesewright et al., describing how the molecule fits into a binding 
pocket requires the ability to define the properties near the molecular surface, and not 
simply as a collection of atoms. 
195
 Normally, this modeling effort would be too 
calculation-intensive with long computer run times. The benefit of the Cresset 
software to simplify and this process and condense the complex three-dimensional 
fields (for example, electrostatic and van der Waals) down to local extrema, called 
field points. These field points are defined for key molecular features, such as H
+
 
donor, H
+
 acceptor, positive/negative ionic character, hydrophobic character, etc. The 
field points are then grouped into field patterns, with these field patterns able to 
compare molecules directly, representing a summary of the 3D properties of each 
molecule. 
In order to evaluate the molecular features against a given biological activity, a 3D 
lattice of grid points is created covering the entire volume surrounding the molecule. 
For each point or each pair of points, a coefficient is then created to define the space. 
The calculation for each coefficient is calculated by: 
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Coeff = (disparity-minDisparity) * ∆Fieldxyz * weight 
Where Coeff is the grid point 
Disparity is the value between two molecules 
MinDisparity is a minimum threshold value 
∆Fieldxyz is the field difference at this point described for this 
molecular pair 
Weight is the product of the molecule and alignment weights 
 
The calculation for the coefficient represented in the above equation helps pinpoint the 
critical regions of the structure activity relationship by looking at each grid point in 
relation to the others.  
 
AVERAGE OF ACTIVES MODELING 
The Average of Actives Analysis Model describes the common attributes that the 
active molecules in the data set have in common. This calculation is performed for all 
field points and at each grid point surrounding the molecules.  Building on the Activity 
Cliff modeling, the Average of Actives is a summary of the Activity Cliff modeling 
and also creates a 3D lattice of grid points of the lattice surrounding the aligned 
molecules and calculates a coefficient. The coefficient for the Average of Actives 
modeling is calculated according to the equation 
196
: 
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Coeff = Fieldxyz * Weight 
Where Coeff is the coefficient for the grid point 
Fieldxyz is the field at the grid point for the active molecule 
Weight is the product of the molecule and alignment weights 
 
RESULTS 
The results of the Activity Cliff Analysis show distinct difference between the 
sulfonylurea analogs interactions with ABC transporters, Pgp and BCRP. To ensure 
robust calculations, the molecules were energy minimized using the MMFF94 energy 
field, and then conformer generation was performed to ensure the molecular structure 
disparity was minimized to eliminate variability and allow for the modeling to be 
governed only by the biological activity of the aligned structures. 
In performing the comparative analysis differentiating the model systems, we 
compared the BCRP activity data against the Pgp activity data (Figure 2). As shown in 
the Figure, there is good correlation between the Pgp and BCRP activity, with a 
linearity score of 0.84 This correlation shows that the nature of transport for the two 
proteins is similar, with more sulfonylurea analogs substrate of Pgp than that of 
BCRP, as shown by the activity. This proved a very interesting point as the 
understanding was that Glyburide (and by assumption, the sulfonylurea class) would 
show more substrate activity with BCRP, as is reported in literature. 
1-8
 The activity 
map detailing the Pgp activity to that of BCRP is shown in Figure 34. 
 
           
92 
 
 
Figure 34. Activity map of the sulfonylurea analogs tested in the Pgp and BCRP efflux 
assays. 
 
Also shown in the Pgp and BCRP activity map in Figure 33 there are three regions 
that describe the activity of the sulfonylurea analogs and the Pgp and BCRP 
transporter proteins.  For reference, Glyburide is the red dot in the center of the graph 
(data points 0.45 BCRP and 0.8 Pgp) and splits the activity data into three distinct 
categories: Pgp/BCRP activity less than Glyburide, Pgp/BCRP activity similar to 
Glyburide, and Pgp/BCRP activity greater than Glyburide. The molecules with Pgp 
and BCRP activity less than Glyburide are straightforward to explain as the molecules 
in this group are smaller in molecular weight and, in the preponderance of cases, lack 
the large, lipophilic benzamido ligand. This point is important as it has been shown 
that the first-generation sulfonylureas that are smaller, and less hydrophobic do not 
interact with the ABC transporter proteins as the second generations sulfonylureas 
have been shown to do. 
197
 The analogs that have Pgp/BCRP activity similar to 
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Glyburide are similar in structure, molecular weight, and ligand placement, and 
therefore will behave in a like manner, as expected. The third region is those 
molecules that have increased Pgp/BCRP activity as compared to Glyburide, which 
can be due to change in the physical-chemical properties of the molecules, such as 
molecular weight, lipophilicity, etc.  
As previously reported by our lab, the pharmacophore of the sulfonylurea-Pgp and the 
sulfonylurea-BCRP systems demonstrated different feature points, as shown in Figure 
3. A simple definition of the pharmacophore model is a representation of the steric and 
electronic features that are necessary for the interaction with a protein or a biological 
response. For both of the pharmacophores, the feature points were spread throughout 
the entire molecule, outlining the areas of interest. As shown in Figure 3, there are 
four feature points that are similar in both pharmacophores, with two distinct 
differences. The differences in the Pgp and BCRP pharmacophore models were found 
to be at the amide and benzamido ring moieties, respectively. For reference, the five-
point pharmacophores describing the Pgp and BCRP protein interactions with the 
sulfonylureas are presented in Figure 35. 
 
    
Figure 35. Pharmacophore Models detailing Pgp (left) and BCRP (right) features. 
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The 3D QSAR modeling of drug-protein interactions is also very important to help 
understand the similarities and differences of the two protein models. As we have 
previously demonstrated, the 3D QSAR models identify the molecular features 
responsible for the activity in the space surrounding the molecules. As shown in 
Figure 4, the electrostatic and steric field points (blue and green spheres, respectively) 
of each model are shown overlaid on the most active commercial sulfonylureas 
(Glyburide, Glimepiride, Glisoxepide, Gliquidone, and Glipizide). As discussed in the 
previous chapters, these field points and their corresponding charges aid in the 
understanding of key molecular features but are limited in explaining the activity in 
the 3D space.  
 
         
Figure 36. 3D field points describing model space for Pgp (left) and BCRP (right) 
Pharmacophores. 
 
The Activity Cliff analysis presented in the Cresset Forge® software module provide 
3D visualizations of a molecule set giving clear indications about the electrostatic, 
hydrophobic, and shape features. Taking into account bot pharmacophore and 3D 
QSAR models, the Activity Cliff Analysis was performed to further characterize the 
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sulfonylurea and Pgp/BCRP affinity. This comparison gives insight into the molecular 
attributes influencing the Pgp or BCRP substrate-interaction selectivity. The 3D 
molecular maps of the Activity Cliff Summary describing the activity for the 
sulfonylurea analogs are shown in Figure 37. 
 
 
96 
 
 
 
  Figure 37. Activity cliff summary maps describing the sulfonylurea-Pgp (top) and 
sulfonylurea-BCRP (bottom) activity. 
 
Starting with the Activity Cliff Summary maps, we will describe the molecular 
features needed for each interaction to improve the selectivity of the sulfonylurea 
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analogs for Pgp or BCRP. As shown in the activity summary maps in Figure 5, there is 
a good deal of overlap in the electrostatic, hydrophobic, and shape molecular 
descriptors. However, there is also differences specific to each Pgp and BCRP model 
that can explain the subsequent interaction. For both sets of sulfonylurea-protein 
interactions, there are specific parts of the molecule that play an important role 
regardless of the model. The benzamido, cyclohexyl, and aryl sulfonylurea ligands 
play an important role for the Pgp and BCRP activity. For further clarity, each of the 
modeling summary maps will be individually explained, along with the individual 
summary maps presented in the following sections, and in Figures 38, 39 and 40. 
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ELECTROSTATICS AVERAGE SUMMARY  
 
 
Figure 38. Summary of electrostatics activity for sulfonylurea interaction with Pgp 
(top) and BCRP (bottom). 
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The electrostatics average summary explains where an increase in negative (red) or 
positive charge (blue) will increase activity. As presented in Figure 6, the 
electrostatics summary details the differences in the sulfonylurea interactions needed 
for the Pgp and BCRP proteins. As shown in Figure 37. there are some pronounced 
differences in the results for the negative and positive electrostatic effects of the 
protein-molecule interaction. For the sulfonylurea-Pgp interaction, there is a mix of 
positive and negative charges that influence the activity, encompassing the top portion 
of the sulfonylurea moiety, and surrounding the carbonyl and methoxy groups on the 
benzamido moiety. There is also a slight positive effect needed around the two amides 
of the sulfonylurea moiety. This is different for the sulfonylurea-BCRP interaction has 
an overwhelming positive charge that governs the ligand-protein interaction. This 
positive charge needed for an increase in activity covers the cyclohexyl ring, across 
the sulfonylurea to the central phenyl ring all the way surrounding the carbonyl and 
methoxy groups of the benzamido moiety. 
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 HYDROPHOBICS AVERAGE SUMMARY 
 
Figure 39. Summary of hydrophobics activity for sulfonylurea interaction with Pgp 
(top) and BCRP (bottom). 
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The hydrophobics average summary explains where an increase in hydrophobic 
character will increase or decrease the activity and is described as favorable (green) or 
unfavorable (purple) hydrophobics. As shown in Figure 39, there is some overlap of 
the hydrophobic character between the two models. For the Pgp model, there is 
favorable hydrophobic activity surrounding the entire cyclohexyl ring, the amine, 
chloro, methoxy, and phenyl ring of the chlorine on the benzamido moiety. However, 
there is a small unfavorable hydrophobic activity around the two carbons of the phenyl 
ring between the methoxy and chloro moieties. For the BCRP model, there is 
favorable hydrophobic activity on the farthest carbon atoms of the cyclohexyl ring, 
surrounding the amide group and the chloro group of the benzamido moiety. 
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SHAPE SUMMARY 
 
 
Figure 40.  Summary of shape activity for sulfonylurea interaction with Pgp (top) and 
BCRP (bottom). 
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The shape summary explains where bulky groups are needed to increase the activity 
and is described as favorable (green) or unfavorable (purple) shape. As shown above 
in Figure 40, the shape summary details the differences in the sulfonylurea interactions 
of the Pgp and BCRP proteins. For the Pgp model, there are mostly favorable shape 
descriptors, with two main areas demonstrating unfavorable shape. The favorable 
shape surrounds the cyclohexyl ring, the sulfonyl and carbonyl moieties, and the larger 
feature of the amide, methoxy and chloro of the benzamido ligand. The unfavorable 
shape occurs between the amides and carbonyl of the sulfonylurea moiety. For the 
sulfonylurea- BCRP interaction, there are mostly favorable shapes, encompassing the 
outer ring moieties. Moving from left to right in the depiction above, there are two 
large areas of favorable shape on the bottom half of the cyclohexyl ring through the 
carbonyl of the sulfonylurea, and on the top half of the molecule, surrounding the 
amide, methoxy and chloro moieties of the benzamido ligand of the molecule. 
 
DISCUSSION 
The ABC transporter proteins are responsible for the active transport of substrates into 
and out of cells. Specifically, ABC transporter proteins have gained much notoriety 
for being responsible for the multidrug resistance (MDR) phenomenon in various 
cancer treatments. 
198
 Much work has been done over the years to identify the features 
of a molecules that are responsible for inducing interactions with the ABC efflux 
transporters.
199
  Expanding on that research, many groups have looked to develop 
global models that will identify the universal features of molecules that are substrates 
or inhibitors. 
200
 However, this has proven very elusive as the broad substrate 
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specificity of each of the transporters proteins allows for much overlap for the 
substrate recognition. From a biological standpoint, the overlap of substrate 
recognition is needed and very much an inherent part of the body’s redundant system 
of protection. 
201
 
202 
With this is mind, we endeavored to describe the interaction of a single class of 
compounds, the sulfonylureas, with two prominent ABC transporters, Pgp and BCRP. 
In order to decipher the underlying structure activity relationship of the sulfonylurea 
and ABC transporter proteins, the molecules’ transporter activity was examined by the 
Activity Analysis Cliffs for the electrostatic, hydrophobic, and shape descriptors. The 
first step in this process was to generate the lowest energy conformers, and then 
overlay the molecules on the template molecule, Glyburide. This allowed for the 
activity to be solely a function of the molecular structure, and for the generation of 
field points surrounding the molecules. These field points were then used for the 
visualization and calculation of the Activity Cliff data describing each sulfonylurea-
protein interaction.  
Results of the Activity Cliff analysis study detail many similarities governing the 
activity and interaction between the sulfonylureas and the ABC transporters, Pgp and 
BCRP. To start, the central aryl ring serves as a linker to the benzamido and 
sulfonylurea ligands and does not contribute to the transporter activity calculation. 
There is electrostatic activity in both models surrounding the sulfonylurea and 
carbonyl group. Also, there is a good deal of overlap between the models on the 
favorable shape on activity surrounding the cyclohexyl and benzamido ligands. The 
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hydrophobic summary also details very similar activity surrounding the cyclohexyl 
and benzamido ligands of both models. 
Though the sulfonylurea-protein models are very similar in many of the electrostatics, 
hydrophobics and shape character, there are still some obvious differences. The 
electrostatics Activity Cliff Analysis surrounding the sulfonylurea and carbonyl 
ligands present differently in each model. The BCRP model requires more positive 
charges surrounding the entire molecule, at the sulfonylurea in its entirety, around the 
far side of the central aryl ring, and on the carbonyl of the benzamido ligand. This 
contrasts with the Pgp model which has a mix of negative and positive charges 
governing activity; negative charge around the sulfonylurea and benzamido carbonyl, 
and positive charge surrounding the amides of the sulfonylurea. To describe the 
structure activity relationship for electrostatics descriptor, having more negative 
groups at these locations on the molecule will increase Pgp activity and decrease the 
BCRP activity.  
For the shape activity analysis model there are some considerable differences 
governing the activity for each model. There is a much larger area surrounding the 
molecule in the BCRP model that requires an increase in bulky groups as compared to 
the Pgp model. The BCRP model has favorable bulky groups covering the entire 
cyclohexyl and benzamido ligands. In contrast, the Pgp model has scattered favorable 
bulky groups on the cyclohexyl and sulfonylurea ligands, with a similar though 
slightly smaller favored bulky group surrounding the amide and back side of the 
substituted phenyl ring. To describe the structure activity relationship for the shape 
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descriptor, having bulky groups on the cyclohexyl favors the BCRP activity, whereas 
having bulky groups on the benzamido ligand would benefit both models’ activity. 
For the hydrophobic Activity Analysis model there is a great deal of similarity, with 
only a few small discrepancies governing the activity. The BCRP model has favorable 
hydrophobic character on the far side of the cyclohexyl ring, and above the amide 
ligand. In contrast, the Pgp model has favorable hydrophobic character surrounding 
the whole cyclohexyl group, and surrounding the entire benzamido ligand, wrapping 
the upper section of the molecule. To describe the structure activity relationship for 
the hydrophobics descriptor, increasing the hydrophobic character surrounding the 
benzamido ring would benefit the Pgp activity, whereas increased hydrophobic 
character on the amide and cyclohexyl ring would benefit both Pgp and BCRP 
activity. A summary of the learnings from the electrostatic, hydrophobic, and shape 
activity atlas analysis are presented in Figure 41. 
 
 
Figure 41. Summary of Activity Atlas modeling for the Pgp and BCRP models on 
Glyburide. 
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The Activity Atlas Modeling has proven to be a valuable tool for deciphering the 
structure activity relationships defining the interactions of sulfonylurea analogs with 
Pgp and BCRP transporter proteins. Using the Activity Atlas modeling we were able 
to leverage the three-dimensional insight for a series of sulfonylureas and the 
associated Pgp/BCRP activity, based on electrostatic, hydrophobic, and shape 
descriptors. This led to identifying key molecular features that were missed in our 
previous modeling attempts. The Activity Atlas modeling specifies the need for bulky 
steric groups, an increase in hydrophobic character, and more positively charged 
groups on/near the cyclohexyl ring. Also, the Activity Atlas model specifies the need 
for increased hydrophobic character and bulky steric groups on the benzamido moiety. 
Finally, and representing the difference in activity between the two proteins, the space 
immediately surrounding the sulfonylurea and amide groups require different charges 
to drive the activity, with an increase in negative charge increasing the Pgp activity, 
and an increase in positive charge increasing the BCRP activity. 
 
CONCLUSION 
This is the first summary and comparison of a large series of sulfonylurea analogs 
activity with the ABC transporter proteins, Pgp and BCRP. Based on the work 
previously reported on Glyburide and its unique placental transport activity, we sought 
to define the molecular properties responsible for interaction with the ABC 
transporters in the hopes of learning how to use this information to better design 
pregnancy centered medications. The sulfonylurea analogs tested in our work show a 
higher propensity for Pgp activity as compared to that of BCRP. This means that in 
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our cell-based transport assays, the same molecule had higher activity in the Pgp 
model than in the BCRP model. As the cell-based assays are very sensitive to drug 
concentration effects, we maintained drug concentrations to that were carefully 
selected to not elicit a false positive or negative response.  
Applying the understanding from the activity cliff analysis, the 3D QSAR models 
generated were condensed down to a simple map of the critical points driving the 
structure activity relationship for three descriptors: electrostatics, hydrophobics and 
shape. The Activity Cliff Analysis detailed key similarities and differences governing 
the molecular features driving activity in the Pgp and BCRP protein models. Though 
the electrostatic, hydrophobic, and shape activity cliffs were shared across molecules 
in both models, there are important differences in that could be used to drive the 
sulfonylurea interaction to Pgp or BCRP. In this regard, the Activity Atlas modeling 
proved to be a valuable tool as previously undiscovered features were characterized 
and shown to be of key importance to define the sulfonylurea-Pgp/BCRP activity. 
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Designing Pregnancy Centered Medications: Insights and Recommendations 
The first three chapters detail the evaluation of a series of sulfonylurea analogs in cell-
based transport assays to determine if they are substrates for the ATP binding cassette 
transporter proteins, Pgp and BCRP. The cell lines used in the study were Madin-
Darby Canine Kidney cells, stably transfected for Pgp or BCRP gene overexpression, 
described and characterized in literature and summarized in Chapters 1 and 2. 
Glyburide is the most prescribed oral sulfonylurea medication and has been shown to 
be actively transported by the ABC transporter proteins, specifically Pgp and BCRP, 
but also by various other transporters. Our work examined the interaction of the 
sulfonylurea analogs with Pgp and BCRP, and determined the molecular features 
driving the specific protein activity. We confirmed that the sulfonylureas are 
substrates of both Pgp and BCRP and built pharmacophore and QSAR models 
explaining the Pgp and BCRP activities in the two and three-dimensional space. 
 
The study of Glyburide and the ABC transporters has presented a unique and exciting 
opportunity to learn about tailoring drug delivery for pregnant women. As discussed 
previously, Glyburide has demonstrated unique placental transport due to the active 
transport by the ABC transporters, minimally crossing the placenta and leaving the 
placenta against the concentration gradient. The treatment of Gestational Diabetes 
Mellitus with Glyburide is an interesting case for drug delivery to the receptor 
(pancreatic β-cells), allowing the mother to maintain and control insulin levels for 
proper function, while limiting the exposure of the drug to the fetus (through placental 
transport). Numerous studies have been performed to evaluate the pharmacokinetics 
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and pharmacodynamics of Glyburide during pregnancy detailing: the fetal exposure, 
umbilical cord concentrations, the safety compared to insulin, and placental transport 
assays. However, there has not been extensive research to understand the molecular 
properties responsible for driving the interaction with the ABC transporters 
responsible for the placental transport, for instance, with Pgp instead of BCRP.  
 
Our research demonstrated that the sulfonylurea molecules need to have specific 
physical-chemical parameters to have ABC transporter activity, in Pgp and BCRP. 
These parameters, among many others, speak to the size, shape, and lipophilicity of 
the molecule, governed by the placement of ligands at the appropriate locations on the 
molecule. As discussed in chapters 2 and 3, the sulfonylurea analogs with similar or 
larger molecular weight or molecular volume as compared to Glyburide were more 
likely to be substrates for both Pgp and BCRP. Conversely, sulfonylurea analogs that 
were much smaller in molecular weight and volume, or were missing the 
arylsulfonylurea and benzamido core structure, were not substrates of either Pgp or 
BCRP. We found that these results were consistent with the structure activity 
relationship of the first and second-generation sulfonylureas, with the smaller, first-
generation sulfonylureas being weak substrates of the SUR1 receptor.  The main 
difference between the fist and second-generation sulfonylureas lies in the “core” 
structure found to increase potency of the second-generation sulfonylureas. This 
required core structure is presented in Figure 42, with the benzamido ligand 
highlighted in light blue, and the arylsulfonylurea highlighted in dark blue. 
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Figure 42. Diagram of core structure for each sulfonylurea generation highlighting the 
arylsulfonylurea (dark blue) and the benzamido (light blue) ligand. 
 
Based on the Activity Cliff modeling reported in Chapter 3, our research has shown 
that adding ligands to increase the hydrophobicity and steric hinderance (bulky 
groups) to the substituted benzamido ring and to the amide ligand of the aryl 
sulfonylurea sections of the molecule increase the activity for both Pgp and BCRP. 
Also, we have shown that increasing the positive charge on the cyclohexyl ligand 
attached to the arylsulfonylurea also increases activity for both Pgp and BCRP. We 
found the differences in the Pgp or BCRP activities were connected to two locations 
on the Glyburide molecule: the sulfonylurea and amide moieties on either side of the 
central aryl ring. Specifically, that an increase the positive charge or negative charge at 
these specific locations (figure 43), would make the molecules more likely to be 
BCRP or Pgp substrates, respectively. 
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Figure 43. Summary of Activity Atlas modeling for the Pgp and BCRP models on 
Glyburide. Note: blue circles indicate the key feature placement behind the activity 
differences in each model. 
 
Based on this work presented in chapters 1-3, we present some recommendations to 
design medications for pregnant women based on these learnings from our Glyburide 
case study. First, and assumed, the molecules need to have appropriate safety and 
PK/PD parameters, for example, high protein binding (>99%), high bioavailability 
(80-100%), moderate half-life (4 to 10hrs), to afford predictable and well-behaved 
ADMET (absorption, distribution, metabolism, excretion, toxicology) properties.  
Similarly, important physical-chemical properties would warrant the molecules to be 
at least the same size (Mw of ~500g/mol), volume (molecular vol 424.74), and 
molecular shape (low energy conformer in Figure 44) to interact with binding pockets 
of the target receptor (in this case, SUR1), as well as the placental ABC transporter 
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proteins. Specifically, those molecules fitting the Glyburide pharmacophores need an 
increase in the bulky and hydrophobic ligands on the ends of the molecule, with 
strategically placed electrostatic groups (negative or positive) in the central core to 
enhance the ABC transporter activity. Designing molecules that incorporate these 
molecular features, aligned against the Glyburide pharmacophore for Pgp or BCRP, 
will increase the respective activity. The preceding are all learnings from our research 
to direct the sulfonylurea molecules to interact with one protein or the other. 
 
                                
                  Figure 44. Glyburide low energy conformation used in our research. 
 
For the purpose of keeping drugs out of the placenta, interactions with more than one 
ABC transporter protein would provide a potentially superior solution. For conditions 
requiring treatment in transporter rich areas, for example the blood brain barrier, this 
approach will not work due to the need to cross the tight junctions containing the 
numerous transporters designed for redundant protection. However, for those disease 
states that have receptor targets outside of the area protected by the ABC proteins, this 
approach may be appropriate. Therefore, to design pregnancy centered medications, 
we need to maintain the fetal protection by designing the molecules that interact with 
numerous placental transporters. This would allow for protection of the fetus by the 
115 
 
natural and redundant system of the ABC Transporter proteins, inherent in pregnant 
women and ever increasing over the course of gestation. By design, the molecules 
would interact with more than one ABC transporter, allowing for redundant protection 
of the fetus if an issue arose with one of the transporters in the mother, for example, 
Pgp deficiency or mutation in the BCRP protein reducing the activity.  
To better define this idea, future research efforts will focus on evaluating the substrate 
activity of the sulfonylurea analogs in other ABC transporter proteins known to be 
present in the fetal-placental barrier.  
Following the work presented in this thesis, the two and three-dimensional QSAR 
models would be built for the new sulfonylurea-ABC protein interactions, and the 
respective pharmacophores generated. Aligning the pharmacophore models of each 
ABC transporter against the lowest energy conformation of Glyburide will allow for 
the overlap the key points from each molecule to the overall key pharmacophore 
features. Then, comparing the numerous models against each-other in the Activity 
Analysis software will help describe the needed features for each interaction. And 
finally, this concept will be tested in a more “global mode”, using our sulfonylurea 
activity models to predict and describe the key pharmacophore features and activities 
of other molecular classes.  
As you can imagine, the treatment options for pregnant women is severely limited due 
to the fact that most drugs will cross the placenta and present a safety risk to the fetus. 
Therefore, designing drugs not to cross the placenta would allow doctors to treat 
pregnant women’s conditions without harming the fetus. This would expand the 
treatment options and positively impact the lives and conditions of an entire subset of 
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the population currently overlooked, with the potential to revolutionize treatment 
options. 
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APPENDIX I 
 
Molecule 
Number  
Structure Pgp Papp log Pgp Papp 
1 
 
 
6.39 0.806 
2 
 
 
2.75 0.439 
3 
 
 
6.21 0.793 
4 
 
 
5.51 0.741 
5 
 
 
2.3 0.362 
6 
 
 
0.93 -0.032 
7 
 
 
0.9 -0.046 
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8 
 
 
0.99 -0.004 
9 
 
 
0.53 -0.276 
10 
 
 
0.82 -0.086 
11 
 
 
0.76 -0.119 
12 
 
 
0.7 -0.155 
13 
 
 
0.65 -0.187 
14 
 
 
0.74 -0.131 
15 
 
 
0.55 -0.260 
119 
 
16 
 
 
0.56 -0.259 
17 
 
 
5.40 0.732 
18 
 
 
10.2 1.01 
19 
 
 
4.17 0.620 
20 
 
 
2.99 0.476 
22 
 
 
9.3 0.968 
23 
 
 
2.43 0.386 
24 
 
 
1.33 0.124 
120 
 
25 
 
 
9.73 0.988 
26 
 
 
8.45 0.927 
27 
 
 
3.83 0.583 
28 
 
 
12.8 1.107 
29 
 
 
5.41 0.733 
30 
 
 
2.04 0.310 
31 
 
 
8.52 0.930 
121 
 
32 
 
 
12.9 1.111 
33 
 
 
21 1.322 
34 
 
 
15.3 1.185 
35 
 
 
3.37 0.528 
36 
 
 
1.56 0.193 
37 
 
 
5.08 0.706 
38 
 
 
0.443 -0.354 
39 
 
 
1.62 0.210 
122 
 
40 
 
 
0.682 -0.166 
41 
 
 
1.76 0.246 
42 
 
 
2.24 0.350 
43 
 
 
1.52 0.182 
44 
 
 
1.09 0.04 
45 
 
 
1.34 0.127 
46 
 
 
1.54 0.186 
47 
 
 
3.57 0.553 
48 
 
 
12.4 1.09 
123 
 
49 
 
 
3.05 0.484 
   
  
50 
 
 
5.89 0.770 
51 
 
 
2.89 0.461 
52 
 
 
4.37 0.640 
53 
 
 
12.5 1.097 
54 
 
 
9.38 0.972 
55 
 
 
1.36 0.134 
56 
 
 
57.4 1.759 
124 
 
57 
 
 
5.35 0.728 
58 
 
 
7.64 0.883 
59 
 
 
6.7 0.826 
60 
 
 
16.5 1.217 
61 
 
 
3.62 0.559 
62 
 
 
3.08 0.489 
63 
 
 
9.74 0.989 
64 
 
 
7.81 0.893 
125 
 
65 
 
 
14.3 1.155 
66 
 
 
11.7 1.068 
67 
 
 
1.72 0.236 
68 
 
 
28.4 1.453 
69 
 
 
25.5 1.407 
70 
 
 
7.45 0.872 
71 
 
 
18.1 1.258 
126 
 
72 
 
 
24.3 1.386 
73 
 
 
1.34 0.127 
74 
 
 
1.06 0.025 
75 
 
 
2.93 0.467 
76 
 
 
4.29 0.632 
77 
 
 
0.848 -0.072 
78 
 
 
12.4 1.093 
79 
 
 
6.07 0.783 
127 
 
APPENDIX II 
 
 
Molecule 
Number  
Structure BCRP 
Papp 
log BCRP 
Papp 
1 
 
 
2.78 0.444 
2 
 
 
1.9 0.278 
3 
 
 
3.21 0.506 
4 
 
 
3.45 0.537 
5 
 
 
1.14 0.056 
6 
 
 
1.01 0.004 
7 
 
 
0.88 -0.055 
128 
 
8 
 
 
0.87 -0.060 
9 
 
 
0.67 -0.173 
10 
 
 
0.54 -0.267 
11 
 
 
0.55 -0.259 
12 
 
 
0.59 -0.229 
13 
 
 
0.72 -0.142 
14 
 
 
0.91 -0.040 
15 
 
 
0.44 -0.356 
129 
 
16 
 
 
0.5 -0.301 
17 
 
 
2.32 0.365 
18 
 
 
3.72 0.570 
19 
 
 
2.41 0.382 
20 
 
 
1.76 0.246 
22 
 
 
2.4 0.380211242 
23 
 
 
6.54 0.815577748 
24 
 
 
1.65 0.217483944 
130 
 
25 
 
 
4.18 0.621176282 
26 
 
 
3.67 0.564666064 
27 
 
 
2.72 0.434568904 
28 
 
 
5.43 0.73479983 
29 
 
 
3.34 0.523746467 
30 
 
 
1.49 0.173186268 
31 
 
 
3.37 0.527629901 
131 
 
32 
 
 
4.28 0.631443769 
33 
 
 
3.32 0.521138084 
34 
 
 
7.67 0.884795364 
35 
 
 
3.9 0.591064607 
36 
 
 
1.87 0.271841607 
37 
 
 
2.75 0.439332694 
38 
 
 
0.877 
-
0.057000407 
39 
 
 
1.76 0.245512668 
132 
 
40 
 
 
0.881 -0.055 
56 
 
 
13.1 1.117 
59 
 
 
3.7 0.568 
60 
 
 
8.33 0.920 
63 
 
 
1.3 0.113 
68 
 
 
13.4 1.127 
69 
 
 
6.00 0.778 
133 
 
70 
 
 
4.54 0.657 
71 
 
 
7.45 0.872 
72 
 
 
12.4 1.093 
75 
 
 
2.3 0.361 
76 
 
 
3.13 0.495 
77 
 
 
0.73 -0.136 
78 
 
 
4.11 0.613 
79 
 
 
3.88 0.588 
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